Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 1495. Отображено 100.
12-01-2012 дата публикации

Blood coagulation inducing polymer hydrogel

Номер: US20120009242A1
Автор: Adam Behrens, Bartley P. Griffith, Brendan J. Casey, Peter Kofinas, Trevor A. Snyder
Принадлежит: University of Maryland at Baltimore, UNIVERSITY OF MARYLAND AT COLLEGE PARK

The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Подробнее
Номер записи: 1
10-05-2012 дата публикации

Composite bone cements with a pmma matrix, containing bioactive antibacterial glasses or glassceramics

Номер: US20120115981A1
Автор: Alessandro Bistolfi, Alessandro Masse, Enrica Verne', Giovanni Maina, Marta Miola, Maurizio Crova, Sara Ferraris
Принадлежит: POLITECNICO DI TORINO, Universita degli Studi di Torino

A bone cement comprising an acrylic polymeric component and an inorganic component comprising a bioactive glass or glass-ceramic, comprising at least one metal oxide having an anti-bacterial activity, wherein said glass or glass-ceramic component is adapted to release ions of said metal in contact with physiological fluids. The bone cement performs a sustained antibacterial action, also promoting binding with the tissues with which it is contacted, and it is advantageously employed in the fixation of orthopaedic prostheses, in the production of temporary prostheses and in spinal surgery.

Подробнее
Номер записи: 2
16-08-2012 дата публикации

Reinforced surgical adhesives and sealants and their in-situ application

Номер: US20120209319A1
Автор: Havazelet Bianco-Peled, Ohad Kimhi
Принадлежит: Technion Research and Development Foundation Ltd

In situ application of reinforced adhesive: applying uncured and curable matter to a surface, applying biocompatible inert reinforcing agent comprising at least one curing agent to the uncured composition; allowing curing within subject, cured composition together with the added reinforcing agent being configured to have improved mechanical support and strength.

Подробнее
Номер записи: 3
25-04-2013 дата публикации

FUNCTIONALIZED ADHESIVE FOR MEDICAL DEVICES

Номер: US20130098550A1
Автор: Hadba Robert Ahmad, Sargeant Tim, Stopek Joshua
Принадлежит: COVIDIEN LP

A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry. 1. A method for adhering a medical device to biological tissue comprising:providing a bifunctional adhesive composition having a plurality of reactive members of a first specific binding pair and a plurality of reactive members of a second specific binding pair;providing tissue with a plurality of complementary reactive members of the first specific binding pair;contacting the adhesive composition with the biological tissue, wherein upon contact of the reactive members of the first specific binding pair with the complimentary reactive members of the first specific binding pair associated with the tissue, covalent bonds are formed between the reactive members and the complementary reactive members of the first specific binding pair, thus adhering the adhesive to the tissue;providing a medical device having a plurality of complementary reactive members of the second specific binding pair;contacting the medical device with the adhesive, wherein upon contact of the reactive members of the second specific binding pair with the complimentary reactive members of the second specific binding pair associated with the device, covalent bonds are formed between the reactive members and the complementary reactive members of the second specific binding pair, thus adhering the device to the adhesive composition.2. The method for adhering a medical device to biological tissue according to wherein the members of the first specific binding pair bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction claim 1 , a Diels-Alder reaction and a thiol-ene reaction and the members of the second specific binding pair bind to one another via a reaction selected from the ...

Подробнее
Номер записи: 4
25-07-2013 дата публикации

Light Activated Composite Tissue Adhesives

Номер: US20130190245A1
Автор: Soltz Barbara A., Soltz Robert
Принадлежит:

A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions caused by bacteria and as the consequence of surgical procedures. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound is eradicated resulting in a sterile wound. In other examples, the composite film may instead contain lumichrome or lumiflavin. 1. A composition , comprising:gelatin, wherein a concentration of the gelatin in the composition is in a range of 20% (w/v) to 50% (w/v);collagen, wherein a concentration of the collagen in the composition is in a range of 10% to 40% (w/v); anda chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation.2. A composition in accordance with claim 1 , wherein the chromophore includes riboflavin.3. A composition in accordance with claim 1 , wherein a concentration of the riboflavin in the composition is within a range of 0.1% to 2.0% (w/v).4. A composition in accordance with claim 1 , wherein the concentration of the riboflavin in the composition is substantially equal to 1.0%.51. A composition in accordance claim 1 , wherein the chromophore includes lumiflavin.6. A composition in accordance with claim 1 , wherein the chromophore includes lumichrome.7. A composition in accordance with ...

Подробнее
Номер записи: 5
19-09-2013 дата публикации

High Adhesion Antimicrobial Skin Prep Solution and Related Methods

Номер: US20130239977A1
Автор: JR. James E., McGuire
Принадлежит: entrotech life sciences, inc.

Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution, wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature. Coated substrates, applicators, and related methods are also disclosed. 1. An antimicrobial skin prep solution comprising:a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent;an antimicrobially effective amount of at least one antimicrobial agent; andan amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution,wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature.2. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 2% by weight of the skin prep solution.3. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 5.5% by weight of the skin prep solution.4. The antimicrobial skin prep solution of claim 1 , wherein the at least one adhesive is a hydrogel in the skin prep solution.5. The antimicrobial skin prep solution of claim 1 , wherein the ...

Подробнее
Номер записи: 6
03-10-2013 дата публикации

Methods, Materials and Apparatus for Treating Bone and Other Tissue

Номер: US20130261217A1
Автор: BEYAR Mordechay, GLOBERMAN Oren, Shavit Ronen, Wachsler-Avrahami Hila
Принадлежит: DePuy Spine, Inc.

A bone cement comprising a first component and a second component, wherein contacting the first component and the second component produces a mixture which attains a high viscosity an initial period and the viscosity of the mixture remains relatively stable for a working time of at least 5 minutes after the initial setting period, and the mixture is suitable for in-vivo use. 1. A bone cement comprising:a first component; anda second component,wherein, contacting the first component and the second component produces a mixture which attains a viscosity greater than 500 Pascal seconds within an initial period,wherein the viscosity of the mixture remains between 500 and 2000 Pascal seconds for a working time of at least 5 minutes after the initial period, andwherein the mixture is suitable for in-vivo use.2. The bone cement of claim 1 , wherein the working time is at least 8 minutes long.3. The bone cement of claim 1 , wherein the initial period is less than 3 minutes.4. The bone cement of claim 1 , wherein the initial period does not exceed 1 minute.5. The bone cement of claim 1 , wherein the mixture solidifies after the working time.6. The bone cement of claim 1 , wherein the initial period is less than 3 minutes and the mixture solidifies after the working time7. The bone cement of claim 6 , wherein the first component includes PMMA and Barium Sulfate.8. The bone cement of claim 6 , wherein the second component includes MMA and DMPT.9. The bone cement of claim 6 , wherein the first component includes PMMA claim 6 , Barium 30 Sulfate claim 6 , and Benzoyl Peroxide claim 6 , and wherein the second component includes MMA claim 6 , DMPT claim 6 , and Hydroquinone.10. The bone cement of claim 1 , wherein the viscosity of greater than 500 Pascal-second results at least partly from a polymerization reaction.11. A bone cement comprising:a first component; anda second component,wherein, contacting the first component and the second component produces a mixture which attains a ...

Подробнее
Номер записи: 7
10-10-2013 дата публикации

POST IRRADIATION SHELF-STABLE DUAL PASTE DIRECT INJECTABLE BONE CEMENT PRECURSOR SYSTEMS AND METHODS OF MAKING SAME

Номер: US20130264244A1
Автор: "OMahony Donal", Garigapati Venkat R., Hess Brian, Murphy Matthew E., Sun Wai Adrian
Принадлежит:

The present invention relates to a bone cement precursor system that is presented in the form of two shelf-stable pastes which have been terminally sterilized and are held in separate containers during product transport and storage. When the product is used during surgery, these pastes inject to a site of application through a static mixing device by the action of applied injection force. When the two pastes are mixed, they start to react to each other while injecting out. The resulting composition is highly biocompatible, osteoconductive, injectable, rapid setting and bioresorbable, and is useful in connection with bone repair procedures, for example, in the craniomaxillofacial, trauma and orthopedic areas. 1. A bone cement precursor system comprising:a first container containing an acidic aqueous paste comprising monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA), citric acid, water, glycerol, polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG), anda second container containing an alkaline non-aqueous paste comprising at least one basic calcium phosphate mineral, at least one paste stabilizing agent, a surfactant and a solvent.2. The bone cement precursor system of claim 1 , wherein said system is shelf-stable post terminal sterilization.3. The bone cement of claim 2 , wherein said terminal sterilization is gamma irradiation.4. The bone cement precursor system of claim 1 , wherein the mean particle size of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) is between about 1 μm to about 90 μm.5. The bone cement precursor system of claim 1 , wherein the amount of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) present in said acidic aqueous paste is between about 5% w/w to about 65% w/w based on the total weight of said acidic aqueous paste.6. The bone cement precursor system of claim 4 , wherein the mean particle size of said monocalcium phosphate ...

Подробнее
Номер записи: 8
10-10-2013 дата публикации

Methods of building a body portion

Номер: US20130267026A1
Автор: Peter M. Bonutti
Принадлежит: P Tech LLC

An improved method of implanting cells in the body of a patient includes positioning viable cells on a support structure. One or more blood vessels may be connected with the support structure to provide a flow of blood through the support structure. A support structure may be positioned at any desired location in a patient's body. The support structure may be configured to replace an entire organ or a portion of an organ. An organ or portion of an organ may be removed from a body cells and/or other tissue is removed to leave a collagen matrix support structure having a configuration corresponding to the configuration of the organ or portion of an organ. Alternatively, a synthetic support structure may be formed. The synthetic support structure may have a configuration corresponding to a configuration of an entire organ or only a portion of an organ.

Подробнее
Номер записи: 9
24-10-2013 дата публикации

BIOLOGIC BONDING AGENT

Номер: US20130281549A1
Автор: Bonutti Peter M.
Принадлежит:

A sterile biofilm could be engineered to isolate the glue-like substance while eliminating the adverse properties of the bacteria. The resulting sterile glue-like substance would be used to help the cells stick to the support structure. The engineered biofilm could be added to the support structure in the laboratory that produces the support structure or just prior to the addition of the cells by the user. Alternatively, the biofilm and support structure could be combined intra-corporally. This biofilm also could be used as an independent polysaccharide based adhesive with mild to moderate adhesion forces. The biofilm could serve as a surgical adhesion or grouting for cells, for tissue fixation (soft tissue to soft tissue, soft tissue to bone, etc.) and as a sealant. The biofilm could be used in conjunction with other implants and devices. The biofilm could be used to coat a stent. 1. A biologic bonding agent comprising:an engineered adhesive derived at least in part from a bacterial source; andthe adhesive being configured to be collected, processed to be substantially free of viable bacteria, and placed in a container,wherein adhesive properties of the bacterial source are substantially maintained.2. The bonding agent of claim 1 , wherein the bacterial source includes biofilm.3. The bonding agent of claim 1 , wherein at least a portion of the adhesive is polysaccharide based.4. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of an implant.5. The bonding agent of claim 1 , wherein at least a portion of the adhesive is biodegradable.6. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of a stent.7. The bonding agent of claim 1 , wherein the adhesive is configured to be applied to at least a portion of a collagen material.8. The bonding agent of claim 1 , wherein the adhesive is configured to promote attachment of cells to a ...

Подробнее
Номер записи: 10
07-11-2013 дата публикации

MEDICAL ADHESIVE FILM

Номер: US20130295345A1
Автор: GUAN Hongxia, PEI Fuxing, Peng Bo, SONG Jiuhong
Принадлежит:

An adhesive film including an upper surface including a developing reference axis. The adhesive film is simple in structure, accurate in positioning, and convenient for practice. 12. An adhesive film , comprising an upper surface comprising a developing reference axis ().223. The adhesive film of claim 1 , wherein the developing reference axis () is provided with reference numbers ().3. The adhesive film of claim 2 , wherein{'b': 1', '1, 'i': a,', 'b, 'the adhesive film comprises an uppermost adhesive film and a plurality of layers of inner adhesive films (. . . );'}{'b': 1', '1, 'i': a,', 'b, 'the inner adhesive films (. . . ) are disposed beneath the uppermost adhesive film;'}{'b': 2', '2', '2, 'i': a,', 'b, 'each of the inner adhesive films comprises an upper surface comprising a reference axis (. . . ) being the same as the developing reference axis () arranged on the uppermost adhesive film; and'}{'b': 2', '2, 'i': a,', 'b, 'the reference axis (. . . ) arranged on each of the inner adhesive films superposes with one another.'}4221133a,ba,ba,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film (. . . ) is provided with reference numbers (. . . ).52. The adhesive film of claim 1 , wherein the developing reference axis () is in a grid structure formed by arranging transverse lines and vertical lines at equal intervalss between each other.622a,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.722a,b. The adhesive film of claim 4 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.82. The adhesive film of claim 5 , wherein vertical lines and/ or transverse lines of the developing reference axis () ...

Подробнее
Номер записи: 11
21-11-2013 дата публикации

COMPOSITION CONTAINING INJECTABLE SELF-HARDENED APATITE CEMENT

Номер: US20130309214A1
Автор: Fazan Fazilah Binti, Ibrahim Shirin Binti, Kader Bashah Nor Shahida Binti, Sabudin Salina, Sahid Sudirman Bin, Wan Sulaiman Wan Ruzaini Bin
Принадлежит: SIRIM Berhad

A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle. 1. A composition of injectable self-hardened apatite cement comprising:{'sub': 3', '4', '2', '4', '4', '2, 'a. a main matrix comprising tri-calcium phosphate (TCP; Ca(PO)) and tetra-calcium phosphate (TTCP; Ca(PO)O),'}{'sub': 2', '3', '6', '8', '7', '6', '5', '3', '7', '2, 'b. hardening agents comprising sodium carbonate (NaCO), citric acid, (CHO) and sodium citrate (CHNaO.2HO),'}c. setting fluids andd. filler and pH stabiliser.2. The composition according to wherein the filler and pH stabiliser is hydroxyapatite (Ca(PO)(OH)).3. The composition according to claim 1 , wherein the weight ratio of tri-calcium phosphate to tetra-calcium phosphate is in the range of 45:55 to 55:45.4. The composition according to claim 1 , wherein said sodium carbonate is present in an amount ranging from about 5 to 10 weight percentage.5. The composition according to claim 1 , wherein said citric acid is present in an amount ranging from about 20 to 30 weight percentage.6. The composition according to claim 1 , wherein said sodium citrate is present in an amount ranging from about 5 to 10 weight percentage.7. The composition according to claim 1 , wherein said filler and/or pH stabiliser is present in an amount ranging from about 1 to 5 weight percentage.8. The composition according to claim 1 , wherein the setting fluids are selected from a ...

Подробнее
Номер записи: 12
05-12-2013 дата публикации

TISSUE ADHESIVE BASED ON NITROGEN-MODIFIED ASPARTATES

Номер: US20130325062A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention. 115-. (canceled)18. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched saturated organic radical optionally also substituted in the chain with heteroatoms.19. The polyurea system as claimed in claim 16 , wherein the radicals Rand Rin each case independently of one another are linear or branched C1 to C10 organic radicals.20. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched claim 17 , saturated claim 17 , aliphatic C2 to C6 claim 17 , and the radicals Rand Rin each case independently of one another are linear or branched C2 to C4 aliphatic hydrocarbon radicals.21. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyesterpolyols and/or polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.22. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.23. The polyurea system as claimed in claim 16 , wherein the polyols A2) ...

Подробнее
Номер записи: 13
06-03-2014 дата публикации

TISSUE ADHESIVE WITH ACCELERATED CURING

Номер: US20140066981A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a polyurea system encompassing as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which can in particular have a number average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6, as component B) amino-functional compounds of general formula (I) in which X is an organic residue comprising a tertiary amino function, having no Zerewitinoff active hydrogen, Ris a CH—COORresidue, in which Ris an organic residue having no Zerewitinoff active hydrogen, a linear or branched C1 to C4 alkyl residue, a cyclopentyl or cyclohexyl residue or H, Ris an organic residue having no Zerewitinoff active hydrogen, n is an integer ≧2 or ≦3, in particular for closing, binding, bonding or covering cell tissue, and to a metering system for the polyurea system according to the invention. 114-. (canceled)17. The polyurea system according to claim 16 , wherein R claim 16 , R claim 16 , Rare claim 16 , each independently of one another or simultaneously claim 16 , a linear or branched claim 16 , saturated organic residue that is optionally also substituted in the chain with heteroatoms claim 16 , in particular a linear or branched claim 16 , saturated claim 16 , aliphatic C1 to C10 claim 16 , preferably C2 to C8 and particularly preferably C2 to C6 hydrocarbon residue.18. The polyurea system according to claim 17 , wherein R claim 17 , R claim 17 , Rare claim 17 , each independently of one another or simultaneously claim 17 , a methyl claim 17 , ethyl claim 17 , propyl or butyl residue claim 17 , wherein at least one of R claim 17 , R claim 17 , Ris a methylene claim 17 , ethylene claim 17 , propylene or butylene residue.19. The polyurea system according to wherein R claim 15 , Rand optionally Rare claim 15 , each independently of one another or simultaneously claim 15 , a linear or branched C1 to C10 claim 15 , preferably C1 to C8 claim 15 , particularly preferably C2 to ...

Подробнее
Номер записи: 14
13-03-2014 дата публикации

POLY(OCTYLCYANOACRYLATE)-POLYISOBUTYLENE POLYMER CONETWORK, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF

Номер: US20140073743A1
Автор: Erdodi Gabor, Gasser Ryan, Kennedy Joseph, Tang Juay Seng
Принадлежит: THE UNIVERSITY OF AKRON

A polymer conetwork formed from the polymerization reaction of octyl-cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)), wherein the ratio of octyl cyanoacrylate to Ø(PIB-CA)is from about 10:1 to about 40:1. 1. A polymer conetwork formed from the polymerization reaction of:{'sub': 3', '3, 'octyl-cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)), wherein the ratio of octyl cyanoacrylate to Ø(PIB-CA)is from about 10:1 to about 40:1.'}2. The polymer conetwork according to claim 1 , wherein polymerization reaction is initiated by nucleophlic groups located on the surface to be covered by the polymer conetwork.3. The polymer conetwork according to claim 2 , wherein the surface to be covered is skin.4. The polymer conetwork according to any of to claim 2 , wherein the polymer conetwork exhibits higher elongation than a homopolymer of octyl cyanoacrylate.5. The polymer conetwork according to any of to claim 2 , wherein the polymer conetwork exhibits a strength of at least 5N and sufficient to maintain two pieces of skin together.6. Use of the polymer conetwork of for wound closure.7. Use of the polymer conetwork of for sealing surgical cuts and puncture wounds.8. Use of polymer conetwork of as an orthopedic sealant.9. Use of polymer conetwork of for repair of torn annulus. This application claims the benefit of U.S. Provisional Patent Application No. 61/441,813, filed Feb. 11, 2011 and claims the benefit of U.S. Provisional Patent Application No. 61/559,778, filed Nov. 15, 2011, both of which are hereby incorporated by reference.This invention relates to a polyisobutylene-based conetwork and, more particularly, to a poly(octyl cyanoacrylate)-polyisobutylene conetwork. In addition to the polymer conetwork, a method of producing the polymer conetwork is provided, as well as a number of uses for the polymer conetwork are disclosed. ...

Подробнее
Номер записи: 15
10-04-2014 дата публикации

BIORESORBABLE EMBOLIZATION MICROSPHERES

Номер: US20140099374A1
Автор: Golzarian Jafar, Weng Lihui
Принадлежит: Regents of the University of Minnesota

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin. 1. An embolic material comprising at least one microsphere comprising carboxymethyl chitosan crosslinked with carboxymethyl cellulose.2. The embolic material of claim 1 , wherein the microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.3. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.4. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.5. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.6. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.7. The embolic material of claim 1 , wherein the microsphere further comprises a therapeutic agent.8. The embolic material of claim 7 , wherein the therapeutic agent comprises a chemotherapeutic agent.9. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one positively charged functional group.10. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one of irinotecan claim 7 , ambroxol claim 7 , or doxorubicin.11. The embolic material of claim 7 , wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.12. The embolic material of claim 1 , wherein ...

Подробнее
Номер записи: 16
04-01-2018 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20180000982A1
Автор: DeAnglis Ashley, Doron Sivan, Nur Israel, Pilpel Yair, Zherdev Yuri
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

Подробнее
Номер записи: 17
14-01-2016 дата публикации

Adhesive Composition

Номер: US20160008505A1
Автор: Jensen Jarl, Keng Ta Kang, Ramjit Ravi
Принадлежит: EUROMED INC.

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—COH, wherein R is a Cto Calkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition. 2. (canceled)3. (canceled)4. (canceled)5. The adhesive composition of further comprising at least one tackifier.6. The adhesive composition of claim 5 , wherein the tackifier is selected from the group consisting of natural rosin claim 5 , modified rosin claim 5 , glycerol ester of natural rosin claim 5 , glycerol ester of modified rosin claim 5 , pentaerythritol ester of natural rosin claim 5 , pentaerythritol ester of modified rosin claim 5 , phenolic-modified terpene resin claim 5 , aliphatic petroleum hydrocarbon resin claim 5 , and cycloaliphatic resin.7. (canceled)8. (canceled)9. The adhesive composition of claim 1 , wherein the base polymer comprises at least two immiscible monomers.10. The adhesive composition of further comprising a hydrophilic fluid-absorbing gum or gel-thickener claim 1 , wherein the gum or gel-thickener is cationic claim 1 , anionic claim 1 , or non-ionic.11. The adhesive composition of claim 10 , wherein the gel-thickener is a water soluble or swellable hydrocolloid or a mixture thereof.12. The adhesive composition of claim 11 , wherein the gel-thickener is selected from a group consisting of carboxymethylcellulose claim 11 , hydroxyethylcellulose (HEC) claim 11 , hydroxypropylcellulose (HPC) claim 11 , pectin claim 11 , carrageenan claim 11 , and gelatin.13. A medical adhesive device comprising an adhesive composition comprising coconut oil claim 11 , a mineral oil claim 11 , and a base polymer.14. The adhesive device of claim 13 , wherein the adhesive composition further comprises a tackifier.15. The adhesive device of claim 14 , wherein the tackifier is ...

Подробнее
Номер записи: 18
08-01-2015 дата публикации

Temporary Embolization Using Inverse Thermosensitive Polymers

Номер: US20150010471A1
Автор: Raymond Jean, Schwarz Alexander
Принадлежит:

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. 1. A method of temporarily embolizing a vascular site in a mammal , comprising the step of:introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily embolizing a vascular site of said mammal.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein the transition temperature of said inverse thermosensitive polymer is between about 10 C and about 40 C.4. The method of claim 1 , wherein the volume of the inverse thermosensitive polymer between its transition temperature and physiological temperature is between about 80% and about 150% of the volume of the inverse thermosensitive polymer below its transition temperature.5. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer claim 1 , random copolymer claim 1 , graft polymer claim 1 , or branched copolymer.6. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer.7. The method of claim 1 , wherein said inverse thermosensitive polymer is a polyoxyalkylene block copolymer.8. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer or poloxamine.9. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer.10. The method of claim 1 , wherein said inverse thermosensitive ...

Подробнее
Номер записи: 19
14-01-2021 дата публикации

Adhesive Composition

Номер: US20210008244A1
Автор: Alexei Dmitrievitsj FILIPPOV, Marco DOMPÈ, Maria Magdalena Gerdina KAMPERMAN
Принадлежит: Rijksuniversiteit Groningen

The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties.

Подробнее
Номер записи: 20
03-02-2022 дата публикации

STABLE COMPOSITIONS COMPOSED OF A RADIOPAQUE AGENT AND CYANOACRYLATE MONOMER AND APPLICATIONS THEREOF

Номер: US20220031907A1
Автор: BASSAM Laura, BROADLEY Kenneth, Hynes Stephen, Kim David
Принадлежит:

Described herein are compositions composed of a radiopaque agent and a cyanoacrylate monomer. These compositions cure in situ when administered to a subject and, thus, have numerous biomedical applications. The presence of the radiopaque agent allows the practitioner to visualize the compositions during and immediately after administration to the subject. The compositions are non-toxic and shelf-stable, and can be sterilized to prevent microbial growth. The compositions can be pre-mixed prior to sale and distribution, reducing the need for special training in their use. 2. The composition of claim 1 , wherein the radiopaque agent comprises two groups comprising the structure I.4. The composition of claim 3 , wherein Rand Rare the same alkyl group.5. The composition of claim 4 , wherein Rand Rare each a Cto Calkyl group.6. The composition of claim 4 , wherein Rand Rare each methyl claim 4 , ethyl claim 4 , propyl claim 4 , butyl claim 4 , pentyl claim 4 , hexyl claim 4 , heptyl claim 4 , or octyl.7. The composition of claim 1 , wherein the cyanoacrylate monomer is an alkyl cyanoacrylate monomer claim 1 , a cycloalkyl cyanoacrylate monomer claim 1 , an allyl cyanoacrylate monomer claim 1 , an aryl cyanoacrylate monomer claim 1 , an aralkyl cyanoacrylate monomer claim 1 , a carboxy alkyl cyanoacrylate monomer or an iodo-substituted cyanoacrylate monomer.8. The composition of claim 1 , wherein the cyanoacrylate monomer is a C-Calkyl cyanoacrylate monomer.9. The composition of claim 1 , wherein the alkyl cyanoacrylate monomer is butyl cyanoacrylate monomer.10. The composition of claim 3 , wherein the cyanoacrylate monomer is butyl cyanoacrylate monomer and Rand Rare the same alkyl group.11. The composition of claim 10 , wherein Rand Rare each methyl claim 10 , ethyl claim 10 , propyl claim 10 , butyl claim 10 , pentyl claim 10 , heptyl claim 10 , or octyl.12. The composition of claim 1 , wherein the cyanoacrylate monomer is from 30 wt % to 90 wt % of the composition.13. ...

Подробнее
Номер записи: 21
19-01-2017 дата публикации

VACUUM MIXING SYSTEM AND METHOD FOR THE MIXING OF POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20170014786A1
Автор: Kluge Thomas, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

Vacuum mixing systems and methods mix of polymethylmethacrylate bone cement, the systems and methods comprise at least one cartridge having an evacuable internal space, a pump with a plunger that can be moved by hand to generate a low pressure, and a connecting conduit connecting the internal space of the at least one cartridge to the pump. The pump comprises an operating element that can be operated from outside and is connected appropriately to the plunger such that it is suitable for moving the plunger in the pump by hand such that a low pressure can be generated such that the low pressure of the pump can be used to evacuate gas from the internal space of the at least one cartridge through the connecting conduit. 1. A vacuum mixing system for the mixing of polymethylmethacrylate bone cement , the system comprisingat least one cartridge having an evacuable internal space for mixing of the bone cement,a pump with a plunger movable by hand to generate a low pressure, anda connecting conduit connecting the internal space of the at least one cartridge to the pump,wherein the pump comprises an operating element operable from outside and connected appropriately to the plunger such that it is suitable for moving the plunger in the pump by hand such that a low pressure can be generated such that the low pressure of the pump is usable to evacuate gas from the internal space of the at least one cartridge through the connecting conduit,wherein a cement powder is contained in the cartridge and the vacuum mixing system comprising a container separate from the cartridge, the container containing a monomer liquid, wherein the container is connected via a liquid line to the cartridge, whereby the liquid conduit opens at the front side of the cartridge into the cartridge, and the connection conduit opens on the opposite rear side of the cartridge into the cartridge.2. The vacuum mixing system according to claim 1 , wherein the pump comprises a gas-tight pumping space on the inside ...

Подробнее
Номер записи: 22
21-01-2016 дата публикации

VACUUM MIXING SYSTEM AND METHOD FOR THE MIXING OF POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20160015854A1
Автор: VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

A vacuum mixing system for the mixing of polymethylmethacrylate bone cement comprising at least one cartridge () having an evacuatable internal space () for the mixing of the bone cement, the internal space () of which comprises a cylindrical swept volume, a mixing element () that is arranged in the internal space () of the cartridge () such as to be mobile and can be operated from outside the vacuum mixing system in order to mix the content in the internal space () of the cartridge (), and a dispensing plunger () having a cylindrical external circumference whose first base surface borders a base surface of the internal space () of the cartridge () and which can be or is locked to the cartridge () in detachable manner and which, in the detached state, is mobile in the cylindrical region of the internal space () of the cartridge (). 1. Vacuum mixing system for the mixing of polymethylmethacrylate bone cement , comprising{'b': 4', '104', '5', '105', '5', '105, 'at least one cartridge (, ) having an evacuatable internal space (, ) for the mixing of the bone cement, whereby the internal space (, ) comprises a cylindrical swept volume,'}{'b': 12', '112', '5', '105', '4', '104', '5', '105', '4', '104, 'a mixing element (, ) that is arranged in the internal space (, ) of the cartridge (, ) such as to be mobile and can be operated from outside the vacuum mixing system in order to mix the content in the internal space (, ) of the cartridge (, ), and'}{'b': 2', '102', '5', '105', '4', '104', '4', '104', '5', '105', '4', '104, 'a dispensing plunger (, ) having a cylindrical external circumference whose first base surface borders a base surface of the internal space (, ) of the cartridge (, ) and which can be or is locked to the cartridge (, ) in detachable manner and which, in the detached state, is mobile in the cylindrical region of the internal space (, ) of the cartridge (, ),'}{'b': 1', '101', '2', '102', '1', '101', '2', '102', '5', '105', '1', '101', '2', '102', '2', ' ...

Подробнее
Номер записи: 23
21-01-2016 дата публикации

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Номер: US20160015855A1
Автор: Kobayashi Satoru, Matsuda Noriaki, Nohara Masahiro
Принадлежит: 3D-Matrix Ltd.

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

Подробнее
Номер записи: 24
23-01-2020 дата публикации

ADHESIVE FOR HARD TISSUE BONDING, ADHESIVE KIT FOR HARD TISSUE BONDING, AND BONE CEMENT

Номер: US20200023095A1
Автор: Aida Syuhei, Fukuyama Shigeo, HASHIMOTO Kazuaki, Meguro Takashi, Shibata Hirobumi, Tanaka Shinya
Принадлежит:

An adhesive for hard tissue bonding which has a sufficient pot life and excellent biocompatibility and is replaced with bone over time, and an adhesive kit for hard tissue bonding are provided. In addition, bone cement is provided which has excellent biocompatibility and is replaced with bone over time. An adhesive for hard tissue bonding includes: a cyanoacrylate monomer; and beta-tricalcium phosphate or hydroxyapatite. An adhesive kit for hard tissue bonding includes: a liquid agent containing a cyanoacrylate monomer; and a powdery agent containing beta-tricalcium phosphate or hydroxyapatite. Bone cement includes: a cyanoacrylate polymer; and beta-tricalcium phosphate or hydroxyapatite. 1. An adhesive for hard tissue bonding , the adhesive comprising:a cyanoacrylate monomer, andbeta-tricalcium phosphate or hydroxyapatite.2. The adhesive for hard tissue bonding according to claim 1 ,wherein in the beta-tricalcium phosphate, a part of a calcium position in a crystal is replaced with a magnesium ion by dissolution and some vacancies existing in a crystalline structure are replaced with sodium ions by dissolution.3. The adhesive for hard tissue bonding according to claim 1 ,wherein in the beta-tricalcium phosphate, a part of a phosphorus position in a crystal is replaced with a silicon ion by dissolution.4. The adhesive for hard tissue bonding according to claim 3 , the adhesive further comprising:less than or equal to 5 mol % of the silicon ions with respect to all anion positions.5. The adhesive for hard tissue bonding according to claim 1 ,wherein an average particle diameter of the beta-tricalcium phosphate and the hydroxyapatite is less than or equal to 100 μm.6. The adhesive for hard tissue bonding according to claim 1 ,wherein an average particle diameter of the beta-tricalcium phosphate and the hydroxyapatite is less than or equal to 50 μm.7. The adhesive for hard tissue bonding according to claim 1 ,wherein the beta-tricalcium phosphate and the hydroxyapatite ...

Подробнее
Номер записи: 25
28-01-2021 дата публикации

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

Номер: US20210023260A1
Автор: Aoki Shinya, BANDO Ayako, Goto Kengo, Miura Takashi, Nakagawa Aya, Yang Jingjing
Принадлежит: Mitsui Chemicals, Inc.

The application discloses a composition for hard tissue repair comprising a monomer (A), a polymer powder (B) and a polymerization initiator (C), wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, and the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less, as well as, a kit for hard tissue repair comprising three or more members, in which each of the components of the monomer (A), the polymer powder (B) and the polymerization initiator (C) contained in this composition for hard tissue repair are divided and contained in the members in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer powder (B) and a polymerization initiator (C) , whereinthe polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, andthe cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less.2. The composition for hard tissue repair according to claim 1 , wherein the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 2.5 cumulative % or more claim 1 , and 65 cumulative % or less.3. The composition for hard tissue repair according to claim 1 , wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more and 1.90 or less claim 1 , and the aspect ratio of all of the polymer powder (B) is 1.11 or more and 1.80 or less.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate-based monomer.5. The composition for hard tissue repair according to claim 1 , ...

Подробнее
Номер записи: 26
28-01-2021 дата публикации

POLYMERIC TREATMENT COMPOSITIONS

Номер: US20210023261A1
Автор: Constant Michael J., Cruise Gregory M., Greene Rob, Harris Clayton, Keeley Edward Michael
Принадлежит:

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. A polymeric composition comprising: 'a first monomer including a biodegradable linkage to a visualization agent, and a second monomer including at least one hydroxyl group; and', 'a substantially stable biocompatible polymer comprising a reaction product ofwherein the substantially stable biocompatible polymer is dissolved in a solution.2. The polymeric composition of claim 1 , wherein the visualization agent includes at least one aromatic ring.3. The polymeric composition of claim 2 , wherein the at least one aromatic ring at least one iodine atom.4. The polymeric composition of claim 1 , wherein the solution is a non-physiological solution.5. The polymeric composition of claim 4 , wherein the non-physiological solution is a water miscible solvent.6. The polymeric composition of claim 5 , wherein the concentration of the substantially stable biocompatible polymer in the water miscible solvent is about 1% to about 50%.7. The polymeric composition of claim 1 , wherein the second monomer is hydroxyethyl methacrylate.8. The polymeric composition of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , or Seq. ID 12.9. The polymeric composition of claim 1 , wherein the biodegradable linkage is an ester or a polyester.10. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is a reaction product of 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 ...

Подробнее
Номер записи: 27
04-02-2016 дата публикации

POROUS POLYMER COMPOSITES

Номер: US20160030625A1
Автор: Berg Michael C., Lenhart Joseph L., Mrozek Randy A., Robinette Eric J.
Принадлежит:

Porous polymer composites and methods of preparing porous polymer composites are provided herein. In some embodiments, a method for preparing porous polymer composites may include mixing a first polymer with a solvent and a particulate filler to form a first polymer composition, wherein the amount of particulate filler in the first polymer composition is below a mechanical percolation threshold; and removing the solvent from the first polymer composition to concentrate the first polymer and particulate filler into a second polymer composition having a porous structure, wherein the particulate filler concentration in the second polymer composition is increased above the mechanical percolation threshold during solvent removal. 1. A method of forming a porous polymer composition , comprising:mixing a first polymer with a solvent and a particulate filler to form a first polymer composition, wherein the amount of particulate filler in the first polymer composition is below a mechanical percolation threshold; andremoving the solvent from the first polymer composition to concentrate the first polymer and particulate filler into a second polymer composition having a porous structure, wherein the particulate filler concentration in the second polymer composition is increased above the mechanical percolation threshold during solvent removal.2. The method of claim 1 , wherein the first polymer is at least one of a thermoplastic claim 1 , a physically cross-linked polymer network claim 1 , or a chemically cross-linked polymer network.3. The method of claim 1 , wherein the particulate filler concentration in the first polymer composition is about 2 volume % to about 55 volume %.4. The method of claim 1 , wherein the particulate filler concentration in the second polymer composition is about 3 volume % to about 95 volume % relative to a total volume of solids in the second polymer composition.5. The method of claim 1 , wherein the solvent is removed by at least one of evaporation ...

Подробнее
Номер записи: 28
04-02-2016 дата публикации

TREATMENT FOR BILE LEAKAGE

Номер: US20160030628A1
Автор: Kobayashi Satoru
Принадлежит: 3-D Matrix, Ltd.

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

Подробнее
Номер записи: 29
30-01-2020 дата публикации

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

Номер: US20200030485A1
Автор: Aoki Shinya, BANDO Ayako, Goto Kengo, Hamada Tetsuya, Miura Takashi
Принадлежит: Mitsui Chemicals, Inc.

Disclosed are: a composition for hard tissue repair with excellent penetrability to an adherend such as a cancellous bone and excellent adhesion to an adherend, which comprises a monomer (A), a polymer (B), a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 μm or more; and a kit for hard tissue repair having members in which the components of the monomer (A), the polymer (B), the polymerization initiator (C) and the contrast medium (X) contained in this composition for hard tissue repair are encased in three or more divided groups in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer (B) , a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 μm or more.3. The composition for hard tissue repair according to claim 1 , wherein the contrast medium (X) is barium sulfate or zirconia.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate type monomer.5. The composition for hard tissue repair according to claim 1 , wherein the polymer (B) is a (meth)acrylate-based polymer.6. The composition for hard tissue repair according to claim 1 , comprising 10 to 45 parts by mass of the monomer (A) claim 1 , 54.9 to 80 parts by mass of the polymer (B) and 0.1 to 10 parts by mass of the polymerization initiator (C) (the sum of the components (A) to (C) is taken as 100 parts by mass) claim 1 , and 0.5 to 70 parts by mass of the contrast medium (X).7. The composition for hard tissue repair according to claim 1 , wherein the volume mean particle diameter of the contrast medium (X) is 3.0 to 25.1 μm.8. The composition for hard tissue repair according to claim 1 , wherein the volume mean particle diameter of all particles contained in the composition for hard tissue repair is 32 μm or less.9. A kit for hard tissue repair comprising three or more members claim 1 , in which each of the ...

Подробнее
Номер записи: 30
11-02-2016 дата публикации

COMPOSITIONS HAVING CYLINDRICAL VOLUME, METHODS, AND APPLICATORS FOR SEALING INJURIES

Номер: US20160038347A1
Автор: BEALL Dawson, BRICHETTI Jennifer, MACPHEE Martin, WILMER Belinda
Принадлежит:

Disclosed are solid and frozen haemostatic materials having a rod shape and suitable applicators and plungers for application of such dressings to wounded tissue wherein said dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A haemostatic material for treating wounded internal tissue in a mammal comprising a cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator wherein said cylindrical haemostaic material is made by combining liquid fibrinogen and liquid fibrinogen at about 12° C. to 0° C. and preferable between 4° C.+/−2° C. into a cylindrical mold , freezing and thereafter lyophilizing said material , wherein said fibrinogen component is present in an amount between 1 mg/cmand 75 mg/cmand said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to reduce the flow of fluid from said wounded tissue and/or join or approximate said wounded tissue , wherein said haemostatic material is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator , wherein said fibrinogen component is present in an amount between 1 mg/ml and 37.5 mg/ml and said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized. ...

Подробнее
Номер записи: 31
11-02-2016 дата публикации

MALLEABLE, BIODEGRADABLE HEMOSTATIC AGENT

Номер: US20160038630A1
Автор: VOGT Sebastian
Принадлежит:

A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water. 1. A malleable , biodegradable hemostatic agent comprising a malleable , biodegradable composition having hemostatic properties , the composition containing a mixture of the following components:(a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C.;(b) at least one filling agent at least partially present in particulate form and having a melting temperature above 37° C., wherein component (b) has a solubility at a temperature of 25° C. of at least 100 grams per liter of water and is selected from the group consisting of polymers of at least one alkylene oxide and copolymers of at least one alkylene oxide; and(c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water, wherein component (c) is a saturated fatty acid ester.2. The malleable claim 1 , biodegradable hemostatic agent according to claim 1 , wherein the hemostatic agent has a pH in water at a temperature of 25° C. in a range of 5.0-9.0.3. The malleable claim 1 , biodegradable hemostatic agent according to claim 1 , wherein the hemostatic agent has a pH in water at a temperature of 25° C. in a range of 5.5-8 ...

Подробнее
Номер записи: 32
07-02-2019 дата публикации

CURABLE POLYMERIC MATERIALS AND METHODS OF USING SAME

Номер: US20190038799A1
Автор: Beveridge Nicole Morozowich, Demirgöz Döne, DiZio James P., Griesgraber George W., Kipke Cary A., Klein Andrew P., Rasmussen Jerald K., Touris Athanasios
Принадлежит:

Polymeric materials are disclosed herein that include a Polymer A, a Polymer B, and an oxalate ester or reaction product thereof. Polymer A contains electrophilic reactive groups, and Polymer B contains nucleophilic groups. In certain embodiments, the polymeric materials are free-flowing liquids at 100% solids that can be used, for example, as topical skin adhesives. 2. The two-part reactive composition of claim 1 , wherein Polymer A comprises a range of 25 to 93 weight percent of the monomeric units of Formula (I).3. The two-part reactive composition of claim 1 , wherein Polymer A further comprises a monomeric unit comprising a siloxane group.4. The two-part reactive composition of claim 1 , wherein Polymer A further comprises a monomeric unit formed from a monomer comprising an acidic group selected from the group consisting of acrylic acid claim 1 , 2-carboxyethyl acrylate claim 1 , 2-carboxyethyl acrylate oligomers claim 1 , and combinations thereof.5. The two-part reactive composition of claim 1 , wherein Polymer A further comprises a monomeric unit comprising a plurality of (meth)acryloyl groups.6. The two-part reactive composition of claim 1 , wherein Polymer A has a weight average molecular weight (M) in a range of 10 claim 1 ,000 Daltons to 100 claim 1 ,000 Daltons.7. The two-part reactive composition of claim 6 , wherein the first part further comprises an oligomeric or polymeric additive.8. The two-part reactive composition of claim 7 , wherein the oligomeric or polymeric additive has a weight average molecular weight (M) of less than 10 claim 7 ,000 Daltons.10. The two-part reactive composition of claim 1 , wherein Polymer B has a weight average molecular weight (M) of at least 12 claim 1 ,000 Daltons and a weight average molecular weight (M) of no greater than 100 claim 1 ,000 Daltons.11. The two-part reactive composition of claim 1 , wherein a monomeric unit of the plurality of monomeric units of Polymer B having a primary amino group is a reaction ...

Подробнее
Номер записи: 33
15-02-2018 дата публикации

METHOD AND APPARATUS TO CONTROL THE HETEROGENEOUS FLOW OF BONE CEMENT AND IMPROVE OSSEOINTEGRATION OF CEMENTED IMPLANT

Номер: US20180043053A1
Автор: KHANDAKER Morshed, RIAHINEZHAD Shahram
Принадлежит:

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone. 1. A process providing a method to enhance mechanical stability and osseointegration of PolyMethylMethAcrylate (PMMA) cement with bone in surgeries using a metallic implant , comprising:amending surface areas of said implant using at least one of grooves or ion deposition;mixing nanoparticles as additives with PMMA cement;immobilizing osteoconductive nanomaterials with electrospun nanofibers (ENF), andconstruction of a membrane using said ENF said membrane exhibiting adequate stiffness to control the movement of said cement into said bone,wherein said nanofiber membrane is inserted into a formed cavity in said bone, said PMMA cement is deposited into said nanofiber membrane, and said implant is inserted into said formed cavity.2. The process of claim 1 , wherein microgroves on said implant are coupled with growth factors immobilized collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM).3. The process of claim 1 , wherein fibronectin (FN) and magnesium oxide nanoparticles (MgO NPs) immobilized CG-PCL NFM coating are coupled on said implant.4. The process of claim 1 , further comprising immobilizing cell adhesion matrix protein (collagen claim 1 , fibronectin) and bone growth molecules (rhBMP claim 1 , TGF-β) using said ENF membrane to increase ...

Подробнее
Номер записи: 34
03-03-2022 дата публикации

Hemostatic Composition And Preparation Method Therefor

Номер: US20220062496A1
Автор: Chen Hao, FAN Jie, Shang Xiaoqiang, Xiao Liping, Yu Lisha
Принадлежит:

Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.

Подробнее
Номер записи: 35
26-02-2015 дата публикации

BONE CEMENT COMPOSITION

Номер: US20150056289A1
Автор: Ueda Yoshimichi
Принадлежит:

The purpose of the present invention is to provide a bone cement composition which can have desired biological activity performance and desired radiolucency while enabling the strength of a cured product thereof to be kept. A titanium oxide coating is formed on radiolucent particles to thereby produce composite particles, and the composite particles are added to a bone cement composition. The bone cement composition thus produced can be used suitably for the filling of a bone defect portion and the fixation of an artificial joint and in percutaneous vertebroplasty. The shape of each of the radiolucent particles is preferably granular, and the titanium oxide is preferably of a rutile type. 1. A bone cement composition comprising:(a) a composite particle comprising a particle having radiopacity and a titanium dioxide coating with which the particle having radiopacity is coated, and(b) a base material formation component comprising a methacrylate polymer.2. The bone cement composition according to claim 1 , wherein the particle having radiopacity has a granular shape.3. The bone cement composition according to claim 1 , wherein the composite particle has a median diameter of 0.2 to 7 μm.4. The bone cement composition according to claim 1 , wherein the composite particle has a BET specific surface area of 1 to 30 m/g.5. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises rutile titanium dioxide.6. The bone cement composition according to claim 1 , wherein the composite particle further comprises a silica coating.7. The bone cement composition according to claim 1 , wherein the particle having radiopacity is made of barium sulfate or zirconium dioxide.8. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises 1 to 30% by weight of the composite particle.9. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises 2 to 20% by weight of the ...

Подробнее
Номер записи: 36
26-02-2015 дата публикации

Adhesive Containing Microparticles

Номер: US20150056291A1
Автор: Johnson Peter, Wibaux Anne Marie
Принадлежит: AVERY DENNISON CORPORATION

Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use. 1. An adhesive composition comprising:an adhesive; andmicroparticles dispersed in the adhesive, the microparticles including a matrix material and at least one active agent.2. The adhesive of wherein the adhesive is selected from the group consisting of acrylic adhesives claim 1 , rubber adhesives claim 1 , silicone adhesives claim 1 , polyurethane adhesives claim 1 , and combinations thereof.3. The adhesive of wherein the adhesive is one of a solvent based adhesive and a hot melt adhesive.4. The adhesive of wherein the microparticles have an average span of from about 0.1 microns to about 500 microns.5. The adhesive of wherein the microparticles have an average span of from about 1 micron to about 200 microns.6. The adhesive of wherein the microparticles have an average span of from about 5 microns to about 100 microns.7. The adhesive of wherein the microparticles have an average span of from about 5 microns to about 50 microns.8. The adhesive of wherein the active agent is selected from the group consisting of pain reducing agents claim 1 , analgesics and anti-inflammatory agents claim 1 , corticosteriods claim 1 , antibiotics claim 1 , antimicrobial agents claim 1 , antifungal agents claim 1 , debriding agents claim 1 , antihistamines claim 1 , antiepileptics claim 1 , coronary vasodilators claim 1 , dermatologicals claim 1 , ancillary drugs claim 1 , and combinations thereof.9. The adhesive of wherein the active agent is a pain reducing agent.10. The adhesive of wherein the pain ...

Подробнее
Номер записи: 37
10-03-2022 дата публикации

SURGICAL ADHESIVE ABLE TO GLUE IN WET CONDITIONS

Номер: US20220072195A1
Автор: Delmotte Yves A., Payssan Jonathan
Принадлежит:

Compositions and methods for sealing tissue of a patient in a wet environment are disclosed. 148.-. (canceled)49. A system comprising:a multi-chamber syringe assembly comprising:a first syringe;a second syringe;a syringe housing having two first orifices at a first end and two second orifices at a second end, the syringe housing holding both the first syringe and the second syringe in parallel so that outlets of both the first syringe and the second syringe extend through the first orifices of the first end of the syringe housing and a first plunger of the first syringe and a second plunger of the second syringe extend through the second orifices of the syringe housing;a syringe clip coupled to the first plunger of the first syringe and the second plunger of the second syringe;a transfer port closure adapter having two first inlets at a third end and one second inlet at a fourth end, the third end of the transfer port closure adapter configured to be attached to the first end of the syringe housing so that the outlets of both the first syringe and the second syringe are adapted to the two first inlets of the transfer port closure adapter; anda third syringe with its outlet adapted to the second inlet of the transfer port closure adapter;a first aqueous solution having a pH of about 1 to about 5.5 in the first syringe;a second aqueous solution having a pH of about 6 to about 11 in the second syringe;a dry powder composition comprising a first component having a polymer core substituted with at least two sulfhydryl groups and a second component having a polymer core substituted with at least two sulfhydryl-reactive groups in the third syringe.501. The system of claim , wherein the syringe clip is uncoupable from either the first plunger or the second plunger.511. The system of claim , wherein the transfer port closure adapter allows contents of the first syringe , the second syringe and the third syringe to be selectively mixed.521. The system of claim , wherein the ...

Подробнее
Номер записи: 38
03-03-2016 дата публикации

RADIOACTIVE BONE CEMENT

Номер: US20160058905A1
Автор: Kaneko Tadashi, Keyak Joyce H., Sehgal Varun, Skinner Harry B.
Принадлежит:

A target tissue can be treated with a radioisotope. Some methods for treating a target tissue with a radioisotope include determining a distance between a target tissue and a surface of a matrix material to be positioned adjacent the target tissue and, based on the determined distance, determining an activity to be mixed with the matrix material to obtain a desired activity concentration. Some methods further include mixing the radioisotope with the matrix material. In some embodiments, the matrix material comprises bone cement, and the target tissue is a tumor in a bone. The radioisotope may be a beta-emitting radioisotope mixed in the cement at a concentration to form a radioactive cement. 1. A method of placing a mixture for treating a target tissue in a vertebra , the method comprising:based on (a) an activity concentration of a radioisotope in the mixture, the mixture resulting from combining a matrix material and the radioisotope, and (b) a dose of radiation to be delivered to the target tissue by the radioisotope, determining a distance between the target tissue and a surface of the mixture;placing the mixture in the vertebra, wherein the mixture is configured such that, when the mixture is placed in the vertebra, and when a closest surface of the mixture is at the determined distance away from the target tissue, the mixture delivers substantially the dose to the target tissue independently of a total volume of the mixture placed in the vertebra.2. The method of claim 1 , wherein the mixture is configured such that claim 1 , when the mixture is placed in the vertebra claim 1 , only emissions from the radioisotope within about 2.5 mm of the closest surface reach the target tissue.3. The method of claim 1 , wherein the mixture is configured such that claim 1 , when the mixture is placed in the vertebra claim 1 , only emissions from the radioisotope within about 5 mm of the closest surface of the mixture reach the target tissue.4. The method of claim 1 , further ...

Подробнее
Номер записи: 39
03-03-2016 дата публикации

BONE TREATMENT SYSTEMS AND METHODS

Номер: US20160058906A1
Автор: Kohm Andrew, LUZZI Robert, Shadduck John, Truckai Csaba
Принадлежит:

The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition. 1. A bone cement composition configured to provide a controlled viscosity , comprising:a liquid component comprising a monomer; anda non-liquid component comprising first polymer beads having a first average cross-sectional dimension and comprising a radical initiator at a first amount, and second polymer beads having a second average cross-sectional dimension greater than the first average cross-sectional dimension and comprising the radical initiator at a second amount lower than the first amount.2. The bone cement composition of claim 1 , wherein the initiator is dispersed throughout each of the first polymer beads and the second polymer beads.3. The bone cement composition of claim 1 , wherein the first average cross-sectional dimension is less than 100 microns claim 1 , and the second average cross-sectional dimension is greater than 100 microns.4. The bone cement composition of claim 1 , wherein the first polymer beads and the second polymer beads comprise polymethyl methacrylate polymer (PMMA).5. The bone cement composition of claim 4 , wherein the non-liquid component comprises less than 75 wt % PMMA on the basis of a total weight of the non-liquid component.6. The bone cement composition of claim 1 , wherein the radical initiator comprises benzoyl peroxide (BPO).7. The bone cement composition of claim 6 , wherein the ...

Подробнее
Номер записи: 40
02-03-2017 дата публикации

MULTIBRANCHED BIOADHESIVE COMPOUNDS AND SYNTHETIC METHODS THEREFOR

Номер: US20170056548A1
Автор: Lee Bruce P., Murphy John L., Silvary Sunil
Принадлежит:

The invention describes new synthetic medical adhesives and antifouling coatings which exploit the key components of natural marine mussel adhesive proteins. 137.-. (canceled)38. A bioadhesive construct , comprising: a support suitable for tissue repair or reconstruction; anda multihydroxyphenyl (DHPD) functionalized polymer (DHPp), wherein the multihydroxyphenyl (DHPD) functionalized polymer (DHPp) is applied as a pattern, presenting coated and uncoated regions on the support.39. The bioadhesive construct of claim 38 , wherein the coated region provides initial bonding strength to secure in place the bioadhesive construct upon implantation claim 38 , and the uncoated region provides an unobstructed path for tissue ingrowth into the support.40. The bioadhesive construct of claim 38 , wherein the support comprises at least one of: a natural material and man made materials.41. The bioadhesive construct of claim 40 , wherein the natural material is selected from the group consisting of: collagen claim 40 , pericardium claim 40 , dermal tissues claim 40 , and small intestinal submucosa.42. The bioadhesive construct of claim 40 , wherein the man made material is selected from the group consisting of: polypropylene claim 40 , polyethylene claim 40 , polybutylene claim 40 , polyesters claim 40 , PTFE claim 40 , PVC claim 40 , polyurethanes and combinations thereof.43. The bioadhesive construct of claim 38 , wherein the support comprises tissue that has been cleaned and decellularized.44. The bioadhesive construct of claim 38 , wherein the support is a film claim 38 , a mesh claim 38 , a membrane claim 38 , a nonwoven or a prosthetic.45. The bioadhesive construct of claim 38 , further comprising an oxidant.46. The bioadhesive construct of claim 45 , wherein the oxidant is formulated with the coating.47. The bioadhesive construct of claim 45 , wherein the oxidant is applied to the coating.49. A bioadhesive construct claim 45 , comprising: a support suitable for tissue repair ...

Подробнее
Номер записи: 41
15-05-2014 дата публикации

POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20140135418A1
Автор: VOGT Sebastian
Принадлежит:

The subject matter of the invention is a curable composition for use as bone cement, in particular for augmentation of osteoporotic bone tissue, comprising at least one organic polymer and at least one monomer for radical polymerisation, at least one particulate inorganic additive having a BET surface of at least 40 m/g, whereby the additive comprises covalently bound hydroxyl groups, whereby the composition further comprises at least one fatty acid ester or a mixture of fatty acid esters. Another subject matter of the invention is the use of said composition for augmentation of osteoporotic bone tissue and particularly preferably for vertebroplasty, kyphoplasty, and augmentation of drill holes in osteoporotic bone tissue, as well as a kit for producing said composition. 1. A composition for use as bone cement , comprising at least one organic polymer and at least one monomer for polymerisation , wherein the composition is curable and comprises:at least one monomer for radical polymerisation;{'sup': '2', 'at least one particulate inorganic additive having a BET surface of at least 40 m/g, whereby the additive comprises covalently bound hydroxyl groups; and'}at least one fatty acid ester or a mixture of fatty acid esters.2. Composition according to claim 1 , wherein the composition is a thixotropic and curable fluid or a thixotropic and curable paste.3. Composition according to claim 1 , wherein the at least one fatty acid ester or mixture of fatty acid esters is selected from (i) an ester from converting at least one fatty acid and a mono-alcohol claim 1 , diol claim 1 , triol or polyol each having 1 to 15 C atoms or a polyetherpolyol;(ii) a naturally occurring fatty acid ester or a fatty acid ester of natural origin; and(iii) a mixture containing fatty acid esters from (i) and (ii).4. Composition according to claim 1 , wherein the at least one fatty acid ester or mixture of fatty acid esters is liquid at room temperature (18-25° C.) or at body temperature (approx. ...

Подробнее
Номер записи: 42
20-02-2020 дата публикации

EMBOLIC MATERIAL AND METHOD FOR PRODUCING SAME

Номер: US20200054783A1
Автор: BITO Kenta, HASEBE Terumitsu, Hotta Atsushi
Принадлежит:

An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium. 1. An embolic material comprising:at least one type of polymer: anda liposoluble contrast medium.2. The embolic material according to claim 1 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.3. The embolic material according to claim 1 ,wherein the polymer is biodegradable.4. The embolic material according to claim 1 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate.5. A method for producing an embolic material claim 1 , the method comprising:extruding a raw material containing at least one type of polymer and a liposoluble contrast medium into a solvent, the raw material being in a molten state; andcooling the raw material so as to solidify the raw material.6. The method for producing an embolic material according to claim 5 ,wherein the raw material extruded into the solvent forms spherical shapes.7. The method for producing an embolic material according to claim 5 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.8. The method for producing an embolic material according to claim 5 ,wherein the polymer is biodegradable.9. The method for producing an embolic material according to claim 5 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate. This international application claims the ...

Подробнее
Номер записи: 43
28-02-2019 дата публикации

POLYMER PARTICLES

Номер: US20190062479A1
Автор: Cruise Gregory M., Harris Clayton, Hincapie Gloria
Принадлежит:

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents. 1. A polymer particle comprising:at least one monomer; andat least one crosslinker;wherein the polymer particle has a diameter between about 40 μm and about 1,200 μm and is susceptible to degradation through hydrolysis or enzymatic action, and wherein the degradation provides less than about 10% of the polymer particle intact after about 2 weeks.2. The polymer particle of claim 1 , wherein the polymer particle has a diameter between about 75 μm and about 1 claim 1 ,200 μm.3. The polymer particle of claim 1 , wherein the at least one monomer includes a functional group.4. The polymer particle of claim 3 , wherein the functional group is acrylate claim 3 , acrylamide claim 3 , methacrylate claim 3 , or methacrylamide.5. The polymer particle of claim 3 , wherein the functional group is an acidic ionizable functional group or a basic ionizable functional group.6. The polymer particle of claim 1 , wherein the at least one crosslinker includes at least two functional groups.7. The polymer particle of claim 1 , wherein the at least one crosslinker includes at least one linkage susceptible to degradation through hydrolysis or enzymatic action.9. The polymer particle of claim 7 , wherein the at least one linkage is an ester claim 7 , a thioester claim 7 , a carbonate claim 7 , a peptide cleavable by matrix metalloproteinases claim 7 , a peptide cleavable by matrix collagenases claim 7 , a peptide cleavable by matrix elastases claim 7 , a peptide cleavable by matrix cathepsins claim 7 , or a combination thereof.10. The polymer particle of claim 7 , including a second crosslinker including a second linkage selected from an ester claim 7 , a thioester claim 7 , a carbonate claim 7 , a peptide cleavable by matrix metalloproteinases claim 7 , a peptide cleavable by matrix collagenases claim 7 , a peptide cleavable by matrix ...

Подробнее
Номер записи: 44
12-03-2015 дата публикации

WOUND HEALING COMPOSITIONS INCLUDING CYANOACRYLATE MONOMERS AND PHENYTOIN

Номер: US20150071869A1
Автор: Ruiz, SR. Rafael, Zhang Sheng
Принадлежит:

A monomeric adhesive composition includes a stabilized polymerizable monomer, such as a 1,1-disubstituted monomer, including a cyanoacrylate, and a wound healing agent, wherein the wound healing agent is 5,5-disubstitutedhydantoin, including phenytoin; and a method for making said composition. 1. A composition , comprising 2-octyl cyanoacrylate monomer , an amount of butylated hydroxyl anisole and sulfur dioxide effective to stabilize the 2-octyl cyanoacrylate monomer , and 0.05% to 0.3% by weight of the composition of phenytoin , wherein the composition is a homogeneous mixture.2. The composition of claim 1 , wherein said composition is sterilized claim 1 , and the viscosity of the sterilized composition increases between about 0% and about 40% after sterilization relative to the viscosity of the composition prior to sterilization.3. The composition of claim 1 , further comprising up to 2000 ppm of a polymerization accelerator comprising 18-crown-6 crown ether.4. The composition of claim 1 , further comprising a plasticizing agent selected from the group consisting of tributyl citrate claim 1 , diisodecyl adipate and acetyl tributyl citrate.5. The composition of claim 1 , further comprising a thickening agent selected from the group consisting of a partial polymer of a cyanoacrylate and a triblock copolymer of polyoxyalkylene.6. The composition of claim 2 , wherein the composition is sterilized by irradiation.7. The composition of claim 6 , wherein the composition is sterilized by E-beam irradiation.8. The composition of claim 1 , wherein the composition comprises 0.1% to 0.2% by weight of the composition of phenytoin.9. A kit claim 1 , comprising an applicator and the composition of .10. A method of treating tissue claim 1 , comprising applying the adhesive composition of to a tissue surface claim 1 , and allowing said composition to polymerize on said tissue surface.11. A composition claim 1 , comprising n-butyl cyanoacrylate monomer claim 1 , an amount of ...

Подробнее
Номер записи: 45
17-03-2016 дата публикации

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

Номер: US20160074554A1
Автор: FRIMONTI Enrico, LONGO Luigi Maria, Moro Luigi, REPICI Alessandro
Принадлежит: COSMO TECHNOLOGIES LTD.

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A pharmaceutical composition in the form of an emulsion or a microemulsion comprising:(a) an aqueous phase;(b) an oily phase;(c) at least one surfactant;(d) at least one of poloxamer 188, poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407; and(e) at least one physiologically acceptable excipient;wherein said at least one of poloxamer 188, polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below the critical gelation concentration (CGC), and wherein said composition remains in liquid phase up to a temperature of about 40° C. in vitro.2. The pharmaceutical composition according to claim 1 , wherein said composition has a viscosity below about 150 cP (centipoises).3. The pharmaceutical composition according to claim 1 , wherein said at least one of poloxamer 188 claim 1 , poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below about 15% by weight claim 1 , with respect to the weight of the composition.4. The pharmaceutical composition in form of emulsion or microemulsion according to claim 1 , wherein said at least one of poloxamer 188 claim 1 , polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount between about 5% and about 11% by weight claim 1 , with respect to the weight of the composition.5. The pharmaceutical composition according to claim 1 , wherein said poloxamer 407 is present in ...

Подробнее
Номер записи: 46
24-03-2022 дата публикации

Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof

Номер: US20220088266A1
Автор: Lei Fang, Shuai Yajun, Yang Mingying
Принадлежит:

The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen. 1. A blood coagulation-promoting silk fibroin-polypeptide electrospun membrane , wherein the polypeptide has a sequence of GPRPPSEHLQIT (SED ID NO: 1).2. The silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein the electrospun membrane is made of interwoven silk fibroin nanofibers claim 1 , and the polypeptide is evenly distributed in the nanofibers.3. A preparation method of the blood coagulation-promoting silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein specific preparation steps adopted are as follows:1) dissolving, filtering, dialyzing, concentrating, freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder;2) evenly mixing the silk fibroin freeze-dried powder and the polypeptide GPRPPSEHLQIT (SED ID NO: 1) with a hexafluoroisopropanol solvent;3) electrospinning a mixed solution obtained in step 2) to obtain a silk fibroin-polypeptide electrospun membrane.4. The preparation method of the silk fibroin-polypeptide electrospun membrane according to claim 3 , wherein the mass ratio of the silk fibroin freeze-dried powder:the hexafluoroisopropanol solvent used in the step 2) is 2: 98-20:80.5. The preparation method of the silk fibroin- ...

Подробнее
Номер записи: 47
07-03-2019 дата публикации

OILY COMPOSITIONS

Номер: US20190070332A1
Автор: CAINE Marcus Gordon, CHUNG Shui Ting, DREHER Matthew R., LEWIS Andrew Lennard, Willis Sean Leo
Принадлежит: BIOCOMPATIBLES UK LIMITED

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy. 1. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles comprise a polymer to which iodine is covalently bound.2. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles are sufficiently hydrophobic such that an emulsion prepared according to example 2 herein, using a lipiodol:aqueous phase ratio of 2:1 and in which the aqueous phase contains no contrast agent, is stable for at least 10 minutes at between 18 and 22° C.3. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles, when measured according to Example 4a herein, have a cantilever deflection (measured in volts) of less than that of DC Bead.4. A composition according wherein the particles comprise a polymer to which iodine is covalently bound.5. A composition according to wherein the iodine is bound to an aromatic group claim 1 , which aromatic group is covalently bound to the polymer.6. A composition according to wherein particles comprise a polymer to which iodine is covalently bound claim 1 , and wherein the iodine is present in the particles at a level of at least 30 mg I/ml of packed volume claim 1 , preferably 60 mg iodine per ml PV.7. ...

Подробнее
Номер записи: 48
16-03-2017 дата публикации

HYDROGEL INCLUDING SURFACE-TREATED NANOFIBER AND PREPARATION METHOD THEREOF

Номер: US20170072091A1
Автор: HWANG Dong Soo, Jung Jaehyuk, LEE Do Hoon, Oh Dong Yeop
Принадлежит:

Provided are a bioadhesive hydrogel including surface-treated nanofibers, a preparation method thereof, and use of thereof. The hydrogel including surface-treated nanofibers provided in the present invention may have excellent bioadhesive strength, thereby being widely applied to a bioadhesive, a scaffold for tissue engineering, a carrier for drug delivery, etc. 1. A bioadhesive hydrogel comprising chitin nanofibers or chitosan nanofibers , wherein the nanofibers are surface-treated nanofibers comprising a dihydroxyphenyl moiety , a trihydroxyphenyl moiety , or tannic acid covalently bound to the surface thereof.3. The bioadhesive hydrogel of claim 2 , wherein the surface treatment material having Chemical Formula 1 is selected from the group consisting of gallic acid claim 2 , pyrogallol claim 2 , catechol claim 2 , DOPA (3 claim 2 ,4-dihydroxyphenylalanine) claim 2 , TOPA (3 claim 2 ,4 claim 2 ,5-trihydroxyphenyllalanine) claim 2 , and pyrogallol.4. The bioadhesive hydrogel of claim 2 , wherein the surface treatment material is comprised in an amount of 0.1 to 30% by weight claim 2 , based on 100% by weight of the nanofibers.5. The bioadhesive hydrogel of claim 1 , wherein the hydrogel has an adhesive strength of 5 to 100 Mpa at a relative humidity of 50% claim 1 , and an adhesive strength of 0.05 Mpa to 10 MPa at a relative humidity of 100%.6. The bioadhesive hydrogel of claim 1 , wherein the hydrogel is bioconjugated with a physiologically active substance.7. The bioadhesive hydrogel of claim 6 , wherein the physiologically active substance is a cell claim 6 , a protein claim 6 , a nucleic acid claim 6 , a sugar claim 6 , an enzyme claim 6 , or a mixture thereof.8. The bioadhesive hydrogel of claim 1 , wherein the hydrogel is formed by bonding between the dihydroxyphenyl moiety claim 1 , the trihydroxyphenyl moiety claim 1 , or the tannic acid bound to the chitin nanofibers or the chitosan nanofibers and metal ions by adding the metal ions.9. The bioadhesive ...

Подробнее
Номер записи: 49
16-03-2017 дата публикации

CYANOACRYLATE ADHESIVE COMPOSITION AND METHOD FOR MAKING THE SAME

Номер: US20170072092A1
Автор: CHU Fa-Ter
Принадлежит:

The present invention provides a method for making an adhesive composition. An adhesive substrate comprising at least a first cyanoacrylate monomer is provided and then mixed with a thickening agent containing polycyanoacrylate prepared by polymerization of a second cyanoacrylate monomer initiated with an aqueous solution of ammonium hydroxide or alcohol. In light of low boiling point of ammonium hydroxide and alcohol, they can be easily removed by heating at low temperature. As such, conventional premature polymerization of adhesive substrate owing to addition of a thickening agent containing residual accelerators can be overall improved. 1. A method of making an adhesive composition , comprising the steps of:(a) providing an adhesive substrate, the adhesive substrate comprising at least a first cyanoacrylate monomer; providing a second cyanoacrylate monomer;', 'adding an aqueous solution of ammonium hydroxide or alcohol into the second cyanoacrylate monomer to initiate polymerization and forming a polymer of the second cyanoacrylate monomer; and', 'heating and drying the polymer of the second cyanoacrylate monomer at 30° C-100° C. to remove the ammonium hydroxide or the alcohol; and, '(b) providing a thickening agent, the thickening agent comprising at least a polycyanoacrylate, wherein the polycyanoacrylate is prepared by a method comprising the steps of(c) mixing the thickening agent with the adhesive substrate.2. The method according to claim 1 , wherein the first cyanoacrylate monomer or the second cyanoacrylate monomer is selected from the group consisting of alkyl 2-cyanoacrylate claim 1 , cycloalkyl-2-cyanoacrylate claim 1 , fluoroalkyl-2-cyanoacrylate claim 1 , fluorocycloalkyl-2-cyanoacrylate claim 1 , alkoxyalkyl-2-cyanoacrylate claim 1 , alkoxycycloalkyl-2-cyanoacrylate claim 1 , fluoroalkoxyalkyl-2-cyanoacrylate claim 1 , and mixtures of two or more thereof.3. The method according to claim 2 , wherein the first cyanoacrylate monomer or the second ...

Подробнее
Номер записи: 50
14-03-2019 дата публикации

Particles

Номер: US20190076571A1
Автор: Gregory M. Cruise, Steve Plotkin, Xinping Wu
Принадлежит: MicroVention Inc

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Подробнее
Номер записи: 51
24-03-2016 дата публикации

Method for Producing an Antibiotic Polymethylmethacrylate Bone Cement Powder, and an Antibiotic Polymethylmethacrylate Bone Cement Powder

Номер: US20160082143A1
Автор: VOGT Sebastian
Принадлежит:

The invention relates to a method for producing an antibiotic bone cement, whereby, in a step A), a bone cement base powder with a water content of less than or equal to 1.0% by weight is mixed with trometamol-fosfomycin to form a bone cement powder, and, in a step X), the bone cement powder is dried to a water content of less than or equal to 1.0% by weight. The invention also relates to a bone cement powder that was produced according to said method and contains a bone cement base powder and trometamol-fosfomycin, whereby the bone cement powder has a water content of less than or equal to 1.0% by weight. The bone cement powder is free-flowing and does not clump and can be used for producing bone cements that meet ISO 5833. 1. A method for producing an antibiotic bone cement , comprising:step A), mixing a bone cement base powder with a water content of less than or equal to 1.0% by weight with trometamol-fosfomycin to form a bone cement powder, and,step X), drying the bone cement powder to a water content of less than or equal to 1.0% by weight.2. The method according to claim 1 , wherein the bone cement base powder is a polymer powder comprising a polymer selected from the group consisting of poly(methacrylic acid methylester) claim 1 , poly(methacrylic acid ethylester) claim 1 , poly(methylmethacrylic acid propylester) claim 1 , poly(methacrylic acid isopropylester) claim 1 , poly(methyl-methacrylate-co-methylacrylate) claim 1 , poly(styrene-co-methylmethacrylate) claim 1 , and a mixture of at least two of said polymers.3. The method according to claim 1 , wherein claim 1 , in step A) claim 1 , the amount of bone cement base powder that is admixed to the bone cement powder ranges from 70 to 99.5% by weight.4. The method according to claim 1 , wherein a radiopaquer is additionally admixed to the bone cement powder in step A).5. The method according to claim 4 , wherein the amount of admixed radiopaquer is in the range from 3 to 30% by weight.6. The method ...

Подробнее
Номер записи: 52
26-03-2015 дата публикации

Compliant Surgical Adhesive

Номер: US20150086503A1
Автор: Mefford Olin Thompson, Nagatomi Jiro, Sanders Lindsey, Stone Roland, Webb C. Kenneth
Принадлежит:

Surgical adhesives that include a blend of two different thermoreversible gelling polymers and a crosslinking agent are described. The first thermoreversible gelling polymer is partially or fully acrylated and the second thermoreversible gelling polymer includes dual functionality including acrylate functionality and amine-reactive functionality. The adhesives can provide gelling and covalent crosslinking within the polymers of the adhesive as well as crosslinking with surrounding tissue. 1. A gel-forming composition comprising:a first thermoreversible gelling block copolymer that includes a hydrophilic block and a hydrophobic block, the first thermoreversible gelling copolymer including acrylate functionality in at least a portion of the termini of the copolymer;a second thermoreversible gelling block copolymer that differs from the first thermoreversible gelling block copolymer and includes a hydrophilic block and a hydrophobic block, the second thermoreversible gelling copolymer including acrylate functionality on a portion of the termini of the copolymer and including amine-reactive functionality on a portion of the termini, the hydrophilic block of the second thermoreversible gelling block copolymer being the same or different as the hydrophilic block of the first thermoreversible gelling block copolymer and the hydrophobic block of the second thermo reversible gelling block copolymer being the same or different as the hydrophobic block of the first thermoreversible gelling block copolymer; anda polyfunctional thiol crosslinker;the composition comprising the first thermoreversible gelling block copolymer and the second thermoreversible gelling block copolymer in a blend at a ratio of from about 10:90 to about 90:10 by weight, respectively.2. The composition of claim 1 , wherein the first and/or the second thermoreversible gelling block copolymer includes a polyethylene oxide as the hydrophilic block.3. The composition of claim 1 , wherein the first and/or the ...

Подробнее
Номер записи: 53
12-03-2020 дата публикации

PANCREATIC FISTULA OCCLUSION

Номер: US20200078489A1
Автор: Kobayashi Satoru
Принадлежит:

Methods and materials for occluding a pancreatic fistula are described herein. One method for occluding a pancreatic fistula includes administering an effective amount of a self-assembling peptide solution to a pancreatic fistula, where the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions, thereby occluding the pancreatic fistula. 1. A method for occluding a pancreatic fistula , the method comprising administering an effective amount of a self-assembling peptide solution to a pancreatic fistula , wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions , thereby occluding pancreatic fistula.2. The method of claim 1 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and a hydrophilic amino acids.3. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from RADA claim 1 , IEIK claim 1 , TTTT claim 1 , ATAT claim 1 , TVTV claim 1 , ASAS claim 1 , SSSS claim 1 , VVVTTTT claim 1 , and a combination thereof.4. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from (RADA) claim 1 , (IEIK)I claim 1 , and (KLDL).5. The method of claim 1 , wherein the self-assembling peptide is about 0.1 to about 10 w/v % of the solution or about 0.1 to about 3.5 w/v % of the solution.6. The method of claim 1 , wherein the self-assembling peptide is about 1 claim 1 , about 2.5 claim 1 , or about 3 w/v % of the solution.7. The method of claim 1 , wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof target area.8. The method of claim 1 , wherein the effective amount is approximately 1 mL per 1 cmof target area.9. The method of claim 1 , wherein the hydrogel is formed ...

Подробнее
Номер записи: 54
12-06-2014 дата публикации

STERILIZED LIQUID COMPOSITIONS OF CYANOACRYLATE MONOMER MIXTURES

Номер: US20140163610A1
Автор: Zhang Sheng
Принадлежит: Adhezion Biomedical, LLC

Cyanoacrylate adhesive compositions comprise a mixture of two cyanoacrylate monomers, including 2-octyl cyanoacrylate and n-butyl cyanoacrylate. The monomers are stabilized and sterilized by irradiation, and do not substantially increase in viscosity after sterilization or after two years of shelf storage. These compositions have anti-microbial properties, and may be used to close wounds as well as secure catheters inserted into the body in place. 1. A method for closing a skin ulcer , comprising applying a cyanoacrylate adhesive composition to the skin ulcer and allowing the composition to cure on the ulcer , thereby closing the ulcer , wherein the composition comprises a mixture of about 78% to about 82% by weight of monomeric 2-octyl cyanoacrylate , about 22% to about 18% by weight of monomeric n-butyl cyanoacrylate , about 2000 ppm to about 14 ,000 ppm of butylated hydroxyl anisole , and about 10 ppm to about 200 ppm of sulfur dioxide or about 5 ppm to about 50 ppm of an acid stabilizer selected from the group consisting of sulfuric acid , phosphoric acid , and perchloric acid , wherein the composition is sterilized by electron beam (E-beam) irradiation , wherein the viscosity of the sterilized composition increases by no more than about 300% over a period of at least two years of shelf storage , and wherein the composition does not contain any plasticizer.2. The method of claim 1 , wherein the skin ulcer comprises a pressure ulcer.3. The method of claim 2 , wherein the pressure ulcer comprises a bed sore.4. The method of claim 1 , wherein the composition comprises a mixture of about 79% to about 81% by weight of monomeric 2-octyl cyanoacrylate claim 1 , about 21% to about 19% by weight of monomeric n-butyl cyanoacrylate claim 1 , about 2000 ppm to about 14 claim 1 ,000 ppm of butylated hydroxyl anisole claim 1 , and about 10 ppm to about 200 ppm of sulfur dioxide.5. The method of claim 1 , wherein the composition comprises a mixture of about 79% to about 81% by ...

Подробнее
Номер записи: 55
21-03-2019 дата публикации

COMPOSITE BIOADHESIVE SEALANT

Номер: US20190083676A1
Автор: PINKAS Oded, ZILBERMAN Meital
Принадлежит:

A kit and a bioadhesive, comprising gelatin, alginate, montmorillonite and a coupling agent, which is characterized by rapid curing, optimal viscosity, high burst strength, flexibility, biocompatibility and biodegradability, is disclosed. 1. A kit for forming a bioadhesive , comprising a first container containing a first formulation and a second container containing a second formulation , said first formulation comprises gelatin and alginate and said second formulation comprises a coupling agent for coupling said gelatin and/or for coupling said alginate and/or for coupling said gelatin to said alginate , wherein at least one of said first formulation and said second formulation comprises montmorillonite.2. The kit of claim 1 , wherein a concentration of said gelatin in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 50 mg/ml to 500 mg/ml.3. The kit of claim 1 , wherein a concentration of said alginate in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 5 mg/ml to 100 mg/ml.4. The kit of claim 1 , wherein a concentration of said montmorillonite in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 1 mg/ml to 50 mg/ml.5. The kit of claim 1 , wherein a concentration of said coupling agent in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 1 mg/ml to 40 mg/ml.6. The kit of claim 1 , wherein claim 1 , in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , a concentration of said gelatin ranges from 200 mg/ml to 400 mg/ml claim 1 , a concentration of said alginate ranges from 20 mg/ml to 40 mg/ml claim 1 , a concentration of said ...

Подробнее
Номер записи: 56
30-03-2017 дата публикации

REDUCED EXTRAVASATION OF BONE CEMENT

Номер: US20170086898A1
Автор: Steele Bradley E.
Принадлежит: Kyphon SARL

The risk of bone cement extravasation can be reduced by delivering a calcium-dependent polymerizing sealant into a bone structure prior to delivery of bone cement into that structure. The polymerization of the sealant in response to the calcium within the bone structure can fill cracks and any other potential cement leakage paths, thereby minimizing the potential for subsequent extravasation. The benefits of the use of a calcium-dependent polymerizing sealant can be provided in any procedure involving the use of bone cement, such as spinal fixation, vertebroplasty, and kyphoplasty, among others. 1. A method comprising:delivering a calcium-dependent polymerizing sealant into a bone structure;allowing the calcium-dependent polymerizing sealant to polymerize in the bone structure; andsubsequently delivering bone cement into the bone structure.2. The method of claim 1 , wherein the calcium-dependent polymerizing sealant comprises sodium alginate.3. The method of claim 1 , further comprising placing a bone screw into the bone structure claim 1 , wherein the bone screw is engaged with the bone cement.4. The method of claim 3 , wherein delivering the calcium-dependent polymerizing sealant comprises urging the calcium-dependent polymerizing sealant through fenestrations in the bone screw claim 3 , andwherein subsequently delivering the bone cement comprises urging the bone cement through the fenestrations in the bone screw.5. The method of claim 3 , wherein the bone structure comprises a vertebral body claim 3 , andwherein placing the bone screw into the bone structure comprises inserting the bone screw into a pedicle of the vertebral body.6. The method of claim 1 , wherein the bone structure comprises a vertebral body claim 1 , andwherein delivering the calcium-dependent polymerizing sealant comprises:inserting a needle into the vertebral body; andinjecting the calcium-dependent polymerizing sealant into cancellous bone within the vertebral body through the needle.7. The ...

Подробнее
Номер записи: 57
02-04-2015 дата публикации

MICROCOMPOSITES FOR TREATMENT OF BONE

Номер: US20150093443A1
Автор: Botimer Gary, Inceoglu Serkan, Maskiewicz Victoria
Принадлежит:

Compositions having a drug-loaded microparticle and bone cement and methods of making such compositions are disclosed. Also disclosed are methods of employing such compositions for the treatment of injected joint spaces and bone disease. 1. A composition , comprising a particle comprising at least one drug and a porous solid , wherein the particle is dispersed in a bone cement.2. The composition of claim 1 , wherein the at least one drug is an antibiotic claim 1 , a bone growth factor or a chemotherapeutic claim 1 , or a combination thereof.3. The composition of claim 2 , wherein the antibiotic is selected from an aminoglycoside antibiotic claim 2 , a glycopeptide antibiotic claim 2 , a macrolide antibiotic claim 2 , fluoroquinolones claim 2 , sulfa claim 2 , tetracycline claim 2 , rifampin claim 2 , vancomycin claim 2 , cephalosporin claim 2 , penicillinc claim 2 , or a combination thereof.4. The composition of claim 2 , wherein the antibiotic is gentamicin.5. The composition of claim 1 , wherein the porous solid comprises a non-erodible particulate system.6. The composition of claim 1 , wherein the porous solid comprises silica.7. The composition of claim 1 , wherein the particle has a size of about 2 μm to about 200 μm.8. The composition of claim 1 , wherein the bone cement is selected from ALLEGIANCE claim 1 , BONESOURCE claim 1 , CRANIOPLASTIC claim 1 , ORTHOCOMP claim 1 , OSTEOBOND claim 1 , PALACOS claim 1 , PALACOS E-FLOW claim 1 , SIMPLEX P claim 1 , SUCOUR claim 1 , and VERTIFIX.9. The composition of claim 1 , wherein the drug-loading of the particle is about 1% to about 70% by weight of the particle.10. The composition of claim 1 , wherein the drug-loading of the particle is less than about 40% by weight of the particle.11. The composition of claim 1 , wherein the weight ratio of particle to bone cement is about 1:9 to about 7:3.12. The composition of claim 1 , wherein the at least one drug is released over a period of 14 days to 70 days.13. The ...

Подробнее
Номер записи: 58
19-06-2014 дата публикации

METHODS AND COMPOSITIONS SUITABLE FOR IMPROVED REATTACHMENT OF DETACHED CARTILAGE TO SUBCHONDRAL BONE

Номер: US20140170106A1
Автор: Burdon Drew, Carvell Kelsey Jean, Cheng Ruth, Smith Graham
Принадлежит:

The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage. 1. A method for promoting the reattachment of cartilage to bone at a cartilage-bone interface where the delaminated cartilage includes an acellular surface , said method comprising:administering one or more agents to the delaminated cartilage-bone interface, where the agent(s) are suitable for promoting the controlled degradation of the acellular cartilage layer, thereby promoting conditions for the reattachment of said delaminated cartilage to said bone.2. The method of claim 1 , wherein said agent for promoting the controlled degradation of the acellular cartilage layer comprises one or more compositions selected from the group consisting of a poly glycolic acid (PGA) lattice claim 1 , cytokines claim 1 , collagenase claim 1 , hyaluronidase and a material comprising a crystalline compound.3. The method of claim 2 , wherein the material comprising a crystalline compound comprises a depo-corticosteroid.4. The method of claim 1 , wherein said method additionally comprises subchondral disruption of the bone surface.5. The method of claim 1 , wherein said method additionally comprises at least partial removal of calcified cartilage from the bone surface.6. The method of claim 5 , wherein said subchondral disruption of the bone surface removes from approximately 0.02 mm to approximately 3.0 mm of tissue from the surface.7. The method of claim 1 , wherein said controlled degradation of said acellular layer comprises promoting an inflammatory reaction.8. The method of claim 1 , wherein said method additionally comprises administering a biophysically compatible glue or adhesive agent to the cartilage-bone ...

Подробнее
Номер записи: 59
19-03-2020 дата публикации

System for sutureless closure of scleral perforations and other ocular tissue discontinuities

Номер: US20200085995A1
Автор: John J. Whalen, III, Mark E. Thompson, Mark S. Humayun, Niki Bayat, Paulo Falabella, Yi Zhang
Принадлежит: University of Southern California USC

The present disclosure describes, among other things, a thereto-responsive hydrogel comprising a PNIPAM copolymer having adhesive properties that are temperature dependent, as well as a device for administering the hydrogel, and methods for making and using the foregoing.

Подробнее
Номер записи: 60
12-05-2022 дата публикации

SURGICAL ADHESIVES

Номер: US20220143264A1
Автор: BADIE Laetitia, DERAIL Christophe, PAPON Eric, PERRIN Bertrand
Принадлежит:

A composition for the adhesion of biological tissues to one another, for the adhesion of a material to a biological tissue, for the adhesion of an adhesive or of a substance to the surface of a biological tissue, for blocking an orifice in a biological tissue, for reinforcing a biological tissue and/or for fixing and stabilising a biological tissue. A monomer that is polymerisable under the effect of ultraviolet (UV) radiation and in that the viscosity of said composition is less than 10 mPa·s at 20° C. 128-. (canceled)29. A composition , intended to be used in a method for the adhesion of biological tissues to one another , for the adhesion of a material to a biological tissue , for the adhesion of an adhesive or of a substance to the surface of a biological tissue , for blocking an orifice in a biological tissue , for reinforcing a biological tissue and/or for fixing and stabilising a biological tissue , comprising:a polymerisable monomer under the effect of ultra-violet (UV) radiation, and in that its viscosity is less than 10 mPa·s at 20° C.30. The composition according to claim 29 , wherein said UV ray has a wavelength of between 150 nm and 280 nm claim 29 , still more preferably between 170 nm and 260 nm and absolutely preferably between 190 nm and 240 nm.31. The composition according to claim 29 , wherein the polymerisable monomer is only polymerisable by irradiation by UV rays.32. The composition according to claim 29 , wherein it does not comprise polymerisable monomers of which the polymerisation can be initiated just by the contact of water molecules.33. The composition according to claim 29 , wherein it does not comprise polymerisable monomers of the cyanoacrylate family34. The composition according to claim 29 , wherein its viscosity is less than 6 mPa·s at 20° C.35. The composition according to claim 29 , wherein its viscosity is less than 2 mPa·s at 20° C.36. The composition according to claim 29 , wherein said monomer is an acrylate monomer or ...

Подробнее
Номер записи: 61
08-04-2021 дата публикации

Elastic Biopolymer and Use as a Tissue Adhesive

Номер: US20210100928A1
Автор: Annabi Nasim, ASSMANN Alexander, Khademhosseini Ali
Принадлежит:

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics. 175.-. (canceled)76. A tissue adhesive comprising a light activated methacryloyl-substituted gelatin , a photoinitiator and a pharmaceutically acceptable carrier.77. The tissue adhesive of claim 76 , wherein the methacryloyl-substituted gelatin has a degree of methacryloyl substitution between 50% and 90%.78. The tissue adhesive of claim 76 , wherein the methacryloyl-substituted gelatin is present at a concentration between 10% and 40% (w/v).79. The tissue adhesive of claim 76 , wherein the photoinitiator is selected from the group consisting of: 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one claim 76 , azobisisobutyronitrile claim 76 , benzoyl peroxide claim 76 , di-tert-butyl peroxide claim 76 , 2 claim 76 ,2-dimethoxy-2-phenylacetophenone claim 76 , Eosin Y claim 76 , and any combination thereof.80. The tissue adhesive of claim 76 , further comprising:(i) a hemostatic agent selected from the group consisting of blood ...

Подробнее
Номер записи: 62
11-04-2019 дата публикации

RADIOACTIVE LIQUID EMBOLIC

Номер: US20190105425A1
Автор: Cruise Gregory M., Fitz Matthew J., Wu Xinping, Wu Yue
Принадлежит:

Liquid embolic preparations and medical treatment methods of using those preparations are described. In some embodiments, the preparations or solutions can transition from a liquid to a solid for use in the embolization. The preparations can include biocompatible polymers with covalently bound radioactive iodine isotopes. 1. A polymeric composition comprising:a substantially stable biocompatible polymer comprising a reaction product of:a first monomer including a polymerizable moiety having a linkage to a visualization agent having at least one aromatic ring, wherein the at least one aromatic ring includes at least one iodine atom, wherein at least one of the at least one iodine atom is a radioactive isotope,and a second monomer including a polymerizable moiety and at least one hydroxyl group; anda non-physiological solution;wherein the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution.2. The polymeric composition of claim 1 , wherein the linkage is biodegradable.3. The polymeric composition of claim 1 , further including folic acid or a functionalized form thereof.4. The polymeric composition of claim 1 , wherein the radioactive isotope is I claim 1 , I claim 1 , I claim 1 , I claim 1 , or a combination thereof.5. The polymeric composition of claim 1 , wherein the radioactive isotope is I.6. The polymeric composition of claim 1 , wherein the radioactive isotope is I.7. The polymeric composition of claim 1 , wherein the radioactive isotope is I.8. The polymeric composition of claim 1 , wherein the radioactive isotope is I.9. The polymeric composition of claim 1 , wherein the first monomer is functionalized triiodophenol claim 1 , 1-((2-(methacryloyloxy)ethoxy)carbonyloxy)ethyl-3 claim 1 ,5-diacetamido-2 claim 1 ,4 claim 1 ,6-triiodobenzoate claim 1 , 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate claim 1 , or a ...

Подробнее
Номер записи: 63
28-04-2016 дата публикации

PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE

Номер: US20160114075A1
Автор: Brownlee Alan George, Elvin Christopher Malcolm, Lindall Charles Mark, Ramshaw John Alan Maurice, Werkmeister Jerome Anthony
Принадлежит:

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial. 152-. (canceled)53. A method of crosslinking a protein or peptide for use as a tissue sealant , the method comprising:irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a three-dimensional matrix of the tissue sealant.54. The method of claim 53 , wherein the protein or peptide comprises fibrinogen claim 53 , fibrin claim 53 , collagen claim 53 , fibronectin claim 53 , keratin claim 53 , laminin claim 53 , and/or elastin.55. The method of claim 53 , wherein the protein or peptide is isolated from native tissues.56. The method of claim 53 , wherein the protein or peptide is a recombinant protein or peptide.57. The method of claim 53 , wherein the electron acceptor is a persulfate.58. The method of claim 57 , wherein the persulfate is ammonium persulfate or sodium persulfate.59. The method of claim 53 , wherein the photoactivatable metal-ligand complex is an Ru(II) complex.60. The method of claim 59 , wherein the photoactivatable metal-ligand complex is a Ru(II)bipyridyl complex.61. The method of claim 60 , wherein the photoactivatable metal-ligand complex is a tris(bipyridyl)Ru(II) complex62. A method of joining and/or sealing at least one substrate claim 60 , comprising the steps of:applying a tissue sealant comprising: a matrix protein or peptide, a photoactivatable metal-ligand complex, and an electron acceptor to at least one substrate; andirradiating the material to photoactivate the photoactivatable metal-ligand complex, thereby initiating a cross-linking reaction to adhere or join the substrate to an adjacent substrate.63. The ...

Подробнее
Номер записи: 64
10-07-2014 дата публикации

HYDROGEL COMPRISING CATECHOL GROUP-COUPLED CHITOSAN OR POLYAMINE AND POLOXAMER COMPRISING THIOL GROUP COUPLED TO END THEREOF, PREPARATION METHOD THEREOF, AND HEMOSTAT USING SAME

Номер: US20140193360A1
Автор: Lee Haeshin, Lee Moon Sue, RYU Ji Hyun
Принадлежит: Innotherapy Inc.

The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same. 1. A hydrogel composition comprising: (i) a catechol group-coupled chitosan or polyamine; and (ii) a polaxamer thiol group-coupled to the end thereof.2. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a molecular weight of 10 claim 1 ,000 Da˜1 claim 1 ,000 claim 1 ,000 Da.3. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a molecular weight of 50 claim 1 ,000 Da˜200 claim 1 ,000 Da.5. The hydrogel composition of claim 1 , wherein said catechol group-coupled polyamine is any one or more selected from the group consisting of ethylene diamine claim 1 , 1 claim 1 ,3-diaminopropane claim 1 , hexamethylenediamine claim 1 , tetraethylmethylenediamine claim 1 , putrescine claim 1 , cadaverine claim 1 , spermidine claim 1 , spermine claim 1 , linear polyethyleneimine claim 1 , branched polyethyleneimine claim 1 , and ε-poly-L-lysine.6. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a 1-20 mole % of catechol group content to the chitosan or polyamine.7. The hydrogel composition of claim 1 , wherein said polaxamer thiol group-coupled to the end thereof has a 50-100 mole % of thiol group content to the polaxamer.8. The hydrogel composition of claim 1 , wherein the hydrogel composition further comprises a therapeutic drug.9. The hydrogel composition of claim 8 , wherein the therapeutic drug is any one or more selected from the group consisting of human growth hormones ...

Подробнее
Номер записи: 65
09-06-2022 дата публикации

PARTICLES

Номер: US20220176012A1
Автор: Cruise Gregory M., Plotkin Steve, Wu Xinping
Принадлежит:

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer. 1. An embolic composition including:particles including a reaction product of a prepolymer solution including:a polyether macromer; anda monomer including a single ethylenic unsaturation,wherein the embolic composition is configured to fit through an inner diameter of a microcatheter.2. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.0155 inch.3. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.0160 inch.4. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.0165 inch.5. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.0170 inch.6. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.0175 inch.7. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.018 inch.8. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.019 inch.9. The embolic composition of claim 1 , wherein the inner diameter is at most about 0.02 inch.10. The embolic composition of claim 1 , wherein the polyether macromer is a poly(ethylene glycol) diacrylamide macromer claim 1 , a poly(ethylene glycol) diacrylate macromer claim 1 , a poly(ethylene glycol) dimethacrylate macromer claim 1 , a poly(ethylene glycol) dimethacrylamide macromer claim 1 , or a combination thereof.11. The embolic composition of claim 1 , further comprising a visualization agent.12. The embolic composition of claim 11 , wherein the visualization agent is particles of radiopaque materials or halogen containing monomers.13. The embolic composition of claim 12 , wherein the halogen containing monomer is an iodine containing monomer.15. The embolic composition of claim 12 , wherein the particles of radiopaque materials include barium claim 12 , bismuth ...

Подробнее
Номер записи: 66
18-04-2019 дата публикации

IMAGEABLE POLYMERS

Номер: US20190111159A1
Автор: Ashrafi Koorosh, DREHER Matthew R., HOHN Stephane, LEWIS Andrew Lennard, TANG Yiqing, Willis Sean Leo
Принадлежит:

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system 137.-. (canceled)38. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising at least two pendant chains having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;the PVA backbone further comprising 1,3-diol groups acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines.39. Hydrogel polymer microspheres according to wherein the pendant chains comprising cross-linkable ethylenically unsaturated functional groups are attached to the 1 claim 38 ,3-diol groups of the PVA backbone via cyclic acetal linkages.40. Hydrogel polymer microspheres according to wherein the vinylic co-monomer is 2-acrylamido-2-methylpropanesulfonic acid.41. Hydrogel polymer microspheres according to wherein the ethylenically unsaturated functional groups are acrylate groups.42. Hydrogel polymer microspheres according to wherein the radiopaque species comprises an iodinated phenyl group.44. Hydrogel polymer microspheres according to wherein claim 43 , Z is (i) a methylene or ethylene group or is (ii) a group —(CH)—O—(CH)— wherein q is 0 claim 43 , 1 or 2 and p is 1 or 2 or is (iii) absent.45. Hydrogel polymer microspheres according to wherein claim 43 , Z is —CHO— claim 43 , —(CH)O— claim 43 , —CHOCH— claim 43 , —(CH)O(CH)— or is absent.46. Hydrogel polymer microspheres according to wherein Hal is 3 or 4 iodines.47. Hydrogel polymer microspheres according to wherein Hal is 2 claim 43 ,3 claim 43 ,5 triiodo claim 43 , 2 ...

Подробнее
Номер записи: 67
05-05-2016 дата публикации

SINGLE SOLUTION of Gel-LIKE FIBRIN HEMOSTAT

Номер: US20160121017A1
Автор: Falus George
Принадлежит: Biomedica Management Corp

The present invention trademarked ClotGel© is a fibrin II-based hemostat made of two components that are mixed into a single syringe to be delivered as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its cross-linking technology generates an adhesive stable fibrin clot required for hemostasis. The agent consists of a cross-linked gelatin that is homogenized in a solution of fibrin monomer in acetic acid, which is reconstituted before use from a lyophilized fibrin monomer. When both components are mixed into a syringe they produce a viscous gel-like composition that is polymerized and stabilized when in contact with blood. The attachment properties of the composition, as well as the rapid formation of a fibrin clot, ensures that a strong stable blood clot is formed over a bleeding wound within 2 minutes of application. 1. A composition for the control of bleeding in humans with or without compression comprising:a) lyophilized desAB fibrin monomer (fibrin II)b) acetic acid solution for reconstitution of lyophilized fibrin monomerc) cross-linked gelatin2. The composition as claimed in wherein the acetic acid solution has a pH of 3.4-3.5.3. The composition as claimed in wherein the fibrin monomer in acid solution is mixed 5:1 with dihydrate trehalose USP-NF previous to lyophilization.4. The composition as claimed in wherein the mixture of fibrin monomer with trehalose is lyophilized in particles of 50 μm to 200 μm containing at least 20% fibrin II monomer.5. The composition as claimed in wherein the lyophilized fibrin monomer can be reconstituted in less than two minutes by dissolving the fibrin microparticles it in a solution of acetic acid at pH 3.56. the composition as claimed in wherein the fibrin monomer can be reconstituted in acetic acid solution at a concentration ranging from 20 mg/mL to 40 mg/ml.7. ...

Подробнее
Номер записи: 68
05-05-2016 дата публикации

ADHESIVE COMPOSITION FOR SKIN, ADHESIVE FOR SKIN, AND ADHESIVE SHEET FOR SKIN

Номер: US20160121018A1
Автор: OKUYAMA Wataru, WATANABE Ryota
Принадлежит: ALCARE CO., LTD.

An object of the invention is to provide an adhesive composition for skin that gives an adhesive for skin that can be coated readily and is highly cohesive and also an adhesive for skin and an adhesive sheet for skin prepared by using the adhesive composition for skin. 112-. (canceled)13. An adhesive composition for skin , comprising:a UV-curable resin; anda reactive diluent that reacts with the UV-curable resin,wherein the reactive diluent is a (meth)acryloyl group-containing compound.14. The adhesive composition for skin according to claim 13 , wherein a polymerization initiator is bound to a molecular chain of a polymer or oligomer of the UV-curable resin.15. The adhesive composition for skin according to claim 13 , wherein an amount of the UV-curable resin is 30 to 95 mass %; andan amount of a (meth)acryloyl group-containing compound as the reactive diluent is 1 to 30 mass %.16. The adhesive composition for skin according to claim 14 , further comprising a hydrophilic polymer.17. The adhesive composition for skin according to claim 15 , further comprising a hydrophilic polymer.18. The adhesive composition for skin according to claim 15 , further comprising a hydrophilic polymer in an amount of 5 to 20 mass %.19. An adhesive composition for skin claim 15 , comprising:a UV-curable resin in an amount of 30 to 90 mass %;a reactive diluent in an amount of 1 to 30 mass %; anda hydrophilic polymer in an amount of 5 to 20 mass %,wherein a polymerization initiator is bound to a molecular chain of a polymer or oligomer of the UV-curable resin, andthe reactive diluent is a (meth)acryloyl group-containing compound.20. The adhesive composition for skin according to claim 13 , further comprising a functional group-free acrylic polymer.21. The adhesive composition for skin according to claim 14 , further comprising a functional group-free acrylic polymer.22. The adhesive composition for skin according to claim 15 , further comprising a functional group-free acrylic polymer.23. ...

Подробнее
Номер записи: 69
03-05-2018 дата публикации

REMOVABLE FILM FORMING GEL COMPOSITIONS AND METHODS FOR THEIR APPLICATION

Номер: US20180117214A1
Автор: Asmus Robert A., COLAK ATAN SEMRA, Griesgraber George W., Hays David S., Kohler Riedi Petra L., Langer-Anderson Delony L., Pereira Junia M., Rasmussen Jerald K., Solberg Michael J., Wlaschin Katie F., Young Alexi J.
Принадлежит:

Film forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film-forming polymer, a tackifier, and a volatile solvent. The film forming gels can also include antiseptics, cationic polymer coagulants, fillers, and other additives. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing. 1. A film forming gel composition for use as a conformable film bandage , the composition comprising:a silicone containing, film forming polymer;a tackifier comprising a silicate tackifying resin;a coagulant comprising a cationic polymer;and a volatile solvent,wherein a film cast from the composition is self-supporting on a biological substrate and can be peeled off the substrate without substantially compromising the integrity of the film such that at least a portion of the film is removable in a single continuous layer.2. The composition of claim 1 , comprising:a) 10-30 wt. % film forming polymer;(b) 3-20 wt. % tackifier;(c) 60-80 wt. % volatile solvent; and(d) 0.5-20 wt. % cationic polymer;each based on the total weight of the gel composition.3. The composition of claim 1 , wherein the silicone is selected from the group consisting of polydiorganosiloxane polyurea claim 1 , polydiorganosiloxane polyamine claim 1 , polysiloxane carbonate claim 1 , polydiorganosiloxane polyamide claim 1 , and combinations thereof.4. The composition of claim 3 , wherein the polydiorganosiloxane polyamide is a polydiorganosiloxane polyoxamide.5. The composition of claim 1 , further comprising 0.1-15 wt. % silicone surfactant claim 1 , based on the total weight of the gel composition.6. The composition of claim 1 , wherein the coagulant comprises a guanidinyl-containing polymer.7. The composition of claim 6 , wherein the guanidinyl-containing polymer is aminopolymer functionalized with one or more guanidinyl groups.8. The composition of claim 7 , wherein the guanidinyl- ...

Подробнее
Номер записи: 70
07-05-2015 дата публикации

METHOD FOR IMPROVED FIBRIN SEALING

Номер: US20150125440A1
Автор: ILAN Erez, Nur Israel, REGEV KFIR
Принадлежит:

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue. 122-. (canceled)23. A method for treating or preventing a defect in a moist tissue of a subject in need comprising the steps of:a) providing a component comprising solid fibrinogen, providing a component comprising a solid proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen; and providing a liquid fibrin sealant formulation;b) applying an effective amount of the solid components of a) onto at least a part of the moist tissue; andc) applying over at least a portion of the applied solid components an effective amount of the liquid fibrin sealant formulation of a).24. The method according to claim 23 , wherein the moist tissue is not enriched claim 23 , has small amount claim 23 , is deprived or lacks blood vessels and/or is an oozing or non-bleeding tissue.25. The method according to claim 23 , wherein the defect is a leak in the tissue.26. The method according to claim 25 , wherein the leaking substance is not enriched claim 25 , has small amount claim 25 , is deprived or lacks plasma or blood components.27. The method according to claim 23 , wherein the liquid fibrin sealant formulation is provided in solid form and reconstituted prior to its application.28. The method according to claim 23 , wherein the liquid fibrin sealant formulation is provided in frozen form and thawed prior to its application.29. The method according to claim 23 , wherein the solid component is provided in liquid form and dried prior to its application.30. The method according to claim 23 , wherein the solid component is provided in frozen form and dried prior to its application.31. The method according to claim 23 , wherein the solid components are applied simultaneously or one after the other.32. The method according to claim 23 , wherein the liquid components are applied simultaneously or one after the other.33. The ...

Подробнее
Номер записи: 71
25-04-2019 дата публикации

LIQUID APPLICATOR

Номер: US20190117208A1
Автор: GOPALAKRISHNAN Nithinkrishnan, MILLER Guy Stephen, PARISH Simon Mark
Принадлежит:

A liquid applicator () for holding and discharging a curable liquid composition, comprises a receiver body () for holding a curable liquid composition, a discharge tip () having a longitudinal axis and further having a distal end remote from the receiver body () from which the liquid composition is discharged, and a discharge mechanism () for transferring liquid composition held by the applicator () to the tip () for discharge of the composition. The tip () comprises an outlet section () having at least one groove formation () extending along the tip () to the distal end thereof. The applicator may be a surgical adhesive applicator. 125-. (canceled)26. A liquid applicator for holding and discharging a curable liquid composition , the applicator comprising:a receiver body for holding a curable liquid composition, a discharge tip having a longitudinal axis and further having a distal end remote from the receiver body from which the liquid composition is discharged, and a discharge mechanism for transferring liquid composition held by the applicator to the tip for discharge of the composition,wherein the tip comprises an outlet section having at least one groove formation extending along the tip to the distal end thereof.27. The applicator as claimed in wherein said at least one groove formation has a longitudinal axis parallel to the longitudinal axis of the tip.28. The applicator as claimed in wherein a plurality of said groove formations are provided.29. The applicator as claimed in wherein said groove formations have their longitudinal axis equiangularly spaced around the longitudinal axis of the tip.30. The applicator as claimed in wherein the tip has a bore extending through the tip to the distal end thereof and the groove formations are formed in the interior wall of the bore.31. The applicator as claimed in wherein the bore has an upstream section of constant cross-section and a downstream section in which said groove formations are provided.32. The applicator ...

Подробнее
Номер записи: 72
27-05-2021 дата публикации

Pectin-Carboxymethylcellulose Mesothelial Sealants and Protectants

Номер: US20210154354A1
Автор: Mentzer Steven James, Servais Andrew Barrett, Valenzuela Cristian David, Ysasi Alexandra Brooke
Принадлежит:

This disclosure relates to pectin-based polymer compositions and methods of use thereof to cover, protect, and seal injuries, e.g., surgical wounds, in a mesothelial tissue. The methods include obtaining a bioadhesive pectin-based polymer composition including a complex of high-methoxyl pectin (HMP) and carboxymethylcellulose (CMC) in a ratio from about 10 to 1 to 1 to 10 by weight; applying the composition to an injured mesothelial tissue; and applying pressure for at least one minute to enable the composition to bind to the mesothelial tissue. 117-. (canceled)18. A method of covering and sealing a wound in an injured mesothelial tissue , the method comprising:providing a bioadhesive pectin-based polymer film, wherein the film comprising: i) high-methoxyl pectin (HMP) or ii) a complex of HMP and carboxymethylcellulose (CMC) in a ratio from about 10:1 to 1:10 by weight, iii) water, and iv) one or more growth factors;applying the film to the wound in the injured mesothelial tissue; andapplying pressure for at least one minute to enable the film to bind to the wound in the injured mesothelial tissue.19. The method of claim 18 , wherein the injured mesothelial tissue is lung pleura claim 18 , and the method is used to seal an air leak in the lungs.20. The method of claim 18 , wherein the injured mesothelial tissue is heart mesothelium claim 18 , and the method is used to cover a wound in the heart.21. The method of claim 18 , wherein the injured mesothelial tissue is bowel mesothelium claim 18 , and the method is used to seal a surgical site in the bowel.22. The method of claim 18 , wherein the injured mesothelial tissue is spleen mesothelium claim 18 , and the method is used to repair a ruptured spleen.23. The method of claim 18 , wherein the complex is a 1:1 ratio by weight of HMP and CMC.24. The method of claim 18 , wherein the bioadhesive pectin-based polymer film is a moldable film having a thickness of about 40 to 3000 microns.25. The method of claim 18 , wherein ...

Подробнее
Номер записи: 73
12-05-2016 дата публикации

Nano-calcium phosphate-coated polymethylmethacrylate-based co-polymer and coating process of the same

Номер: US20160129148A1
Автор: KWOK Sau Kuen Connie, WONG Chi Tak
Принадлежит:

The present invention relates to a method for coating polymethylmethacrylate (PMMA)-based co-polymer beads with nano-calcium phosphate. The method includes synthesizing the PMMA-based co-polymer beads containing hydroxyl pendant group, reacting the calcium salt and phosphate solution with the hydroxyl pendant group on the PMMA-based co-polymer beads, and thickening of the nano-calcium phosphate coating on the PMMA-based co-polymer beads. 1. A bioactive polymethylmethacrylate (PMMA)-based co-polymer , comprising PMMA-based co-polymer beads and nano-calcium phosphate coated on surfaces of the PMMA-based co-polymer beads.2. The PMMA-based co-polymer of claim 1 , wherein the nano-calcium phosphate is coated onto the PMMA-based co-polymer beads through chemical bonding.3. The PMMA-based co-polymer of claim 2 , wherein the PMMA-based co-polymer beads contains multiple hydroxyl pendant groups; the nano-calcium phosphate is formed by chemical reaction with the multiple hydroxyl pendant groups on the PMMA-based co-polymer beads.4. The PMMA-based co-polymer of claim 2 , wherein the PMMA-based co-polymer beads contains multiple hydroxyl pendant groups; one or more of the multiple hydroxyl pendant groups act(s) as one hydroxyl of the nano-calcium phosphate to bond the nano-calcium phosphate to the surface of the PMMA-based co-polymer beads.5. The PMMA-based co-polymer of claim 1 , wherein the PMMA-based co-polymer beads are prepared by emulsion polymerization method from methacrylate-based monomers.6. The PMMA-based co-polymer of claim 1 , wherein the PMMA-based co-polymer is a nanoparticle having a diameter of substantially 10-1000 nm.7. The PMMA-based co-polymer of claim 1 , wherein the PMMA-based co-polymer is a microparticle having a diameter of substantially 1-100 μm.8. The PMMA-based co-polymer of claim 1 , wherein the nano-calcium phosphate has a diameter of substantially 10-1000 nm.9. A method for coating polymethylmethacrylate (PMMA)-based co-polymer beads with nano- ...

Подробнее
Номер записи: 74
12-05-2016 дата публикации

IMIDATED BIOPOLYMER ADHESIVE AND HYDROGEL

Номер: US20160129149A1
Автор: Elisseeff Jennifer H., Strehin Iossif A., Wang Xiaokun
Принадлежит:

Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings. 19.-. (canceled)10. A method for in situ polymerization of a biocompatible polymer in a tissue of the eye of a subject comprising:a) administering to the tissue of the eye of the subject a composition comprising a hydrophilic biologically compatible first polymer, wherein the first polymer is isolated and purified chondroitin sulfate and/or hyaluronic acid functionalized with an imide group, and optionally, at least one second hydrophilic biologically compatible polymer, wherein said second polymer comprises at least one amine group and is capable of reacting with the first polymer, the second polymer being selected from the group consisting of polypeptides, polysaccharides, carbohydrates, heparin sulfate, keratan sulfate, heparin, gelatin, collagen, albumin and copolymers, terpolymers or combinations or mixtures thereof; andb) polymerizing the polymer in the subject.11. The method of claim 10 , wherein the first polymer is isolated and purified chondroitin sulfate functionalized with an imide group.12. The method of claim 10 , wherein the first polymer is isolated and purified hyaluronic acid functionalized with an imide group.13. The method of claim 10 , wherein the tissue is the cornea of the eye of the subject.14. The method of claim 10 , wherein the second polymer is keratan sulfate.15. The method of claim 10 , wherein the second polymer is collagen.16. A method for treating a corneal ectasia in the eye of a subject in need thereof comprising administering to the cornea claim 10 , a therapeutically effective amount of a composition comprising a hydrophilic biologically compatible first polymer claim 10 , wherein the first polymer is isolated and purified chondroitin sulfate and/or hyaluronic acid functionalized with an imide group claim 10 , for a ...

Подробнее
Номер записи: 75
01-09-2022 дата публикации

TRANSFER METHOD FOR TREATING ABRASION WOUNDS WITH CYANOACRYLATE GLUE

Номер: US20220273497A1
Автор: Carlisle Richard Sheldon
Принадлежит:

A method for treating burns and abrasion wounds by applying a cyanoacrylate glue, using a method whereby a quantity of glue is initially applied to a flexible film of releasable material that does not adhere to the glue after it has set, and then transferring said glue to a wound site with light pressure applied through said film sufficient to control bleeding. Said application of glue under pressure will result in a thin layer of glue over the wound site that will react with the moisture present on the wound surface, thus polymerizing quickly and forming a protective coating on the wound that is flexible and sufficient to resist pathogenic penetration while simultaneously allowing the slow passage of moisture at a rate that will maintain an ideal relatively dry condition for the wound, to prevent infections that tend to develop with excessive moisture. 1. A method for treating abrasion and burn wounds with a cyanoacrylate glue comprising ,(a) applying said cyanoacrylate glue to a flexible layer of release film that does not adhere to said glue, and(b) transferring said glue to a wound surface with sufficient pressure applied through said film to control bleeding while maintaining a moist surface on the wound area,(c) allowing a time period of up to five minutes for said glue to react with said moisture and polymerize, and(d) allowing a further time period for the wound to heal with minimal inflammation and produce an ideal cosmetic result.2. A method for treating an abrasion wound comprising the steps ,(a) applying a cyanoacrylate glue to a flexible release film,(b) transferring said glue to the wound using pressure sufficient to control bleeding, wherein the pressure is applied through said film while maintaining a moist wound surface,(c) waiting for a time period of five minutes for said glue to react with said moisture and polymerize, and(d) removing said pressure and said film.3. A method for applying a cyanoacrylate glue to an abrasion comprising ,(a) wrapping ...

Подробнее
Номер записи: 76
01-09-2022 дата публикации

A TISSUE-ADHESIVE MATRIX AND USES THEREOF

Номер: US20220273842A1
Автор: BAHAR Amir, NSEIR MANASSA Nora, OMAR Rodaina
Принадлежит:

Compositions, comprising a first polymer, a second branched polymer, and a third polymer having reactivity to the second polymer, wherein any of the second and the third polymer comprises a tissue-adhesive group, and wherein the second polymer and the third polymer are at least partially crosslinked are disclosed. Matrices, comprising the composition of the invention and optionally an additional polymeric layer are disclosed. Processes for manufacturing the compositions and uses thereof as for bioadhesion and/or repairing damaged tissues are also disclosed. 1. A composition comprising:(i) a first polymer;(ii) a second branched polymer; 'wherein any one of the second and the third polymer comprises a tissue-adhesive group; and wherein (i) said first polymer, and (ii) at least one of said second branched polymer and said third polymer are blended together, so as to form a blended polymeric fiber.', '(iii) a third polymer having reactivity to the second polymer and is at least partially crosslinked to the second branched polymer;'}2. The composition of claim 1 , wherein said blended polymeric fiber is characterized by a melting point of 50 to 150° C.; wherein said blended polymeric fiber is characterized by an average fiber diameter of 0.5 to 10 um; and wherein an average molecular weight of said first polymer ranges from 10 KDa to 900 KDa.3. The composition of claim 1 , wherein said first polymer is selected from the group consisting of: a polyester claim 1 , a polyanhydride claim 1 , a polyacetal claim 1 , a polyorthoester claim 1 , a polyurethane claim 1 , a polycarbonate claim 1 , a polyphosphazene claim 1 , a polyphosphoester claim 1 , a polyether claim 1 , a silicone claim 1 , a polyamide claim 1 , a polysulfone claim 1 , a polyether ether ketone (PEEK) claim 1 , poly(ethylene glycol) claim 1 , polytetrafluoroethylene claim 1 , polyethylene claim 1 , a polysaccharide or any combination or a copolymer thereof.4. The composition of claim 1 , wherein said third ...

Подробнее
Номер записи: 77
23-04-2020 дата публикации

Particles

Номер: US20200121824A1
Автор: Gregory M. Cruise, Steve Plotkin, Xinping Wu
Принадлежит: MicroVention Inc

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Подробнее
Номер записи: 78
02-05-2019 дата публикации

POWDER-LIQUID BONE CEMENT MIXER WITH COMPRESSED GAS CONNECTION

Номер: US20190126224A1
Автор: Kluge Thomas, VOGT Sebastian
Принадлежит:

The invention relates to a device and method for producing a bone cement paste () from a monomer liquid () and a cement powder (). The device includes a cartridge () with a cylindrical interior chamber for mixing the parent components, whereby the interior chamber of the cartridge () is closed on the front side up to a delivery opening for expelling the bone cement paste () from the interior chamber, a delivery plunger () which is arranged in the interior chamber of the cartridge () and which is supported in a linearly movable manner in the direction of the delivery opening, the cement powder (), which is arranged in the interior chamber of the cartridge () between the delivery opening and the delivery plunger (), a monomer receptacle () with an interior chamber in which a monomer liquid container () containing the monomer liquid () is contained, whereby in the monomer receptacle (), a conveying plunger () is arranged movable in the longitudinal direction of the monomer receptacle (), a compressed gas connection (), which is directly connected or connected via a compressed gas line in a pressure-tight manner with the interior chamber of the monomer receptacle (), whereby the conveying plunger () is arranged between the monomer liquid container () and the compressed gas connection () or the compressed gas line in the monomer receptacle (), and a connection () which connects the interior chamber of the monomer receptacle () and the interior chamber of the cartridge () which is permeable for the monomer liquid () but impermeable for the cement powder (), whereby the monomer liquid container () is arranged between the conveying plunger () and the connection (). 1. A device for producing a bone cement paste from a monomer liquid and a cement powder as parent components of the bone cement paste , the device comprising:a cartridge with a cylindrical interior chamber for mixing the parent components, whereby the cylindrical interior chamber of the cartridge is closed on a ...

Подробнее
Номер записи: 79
18-05-2017 дата публикации

DENTAL CEMENT

Номер: US20170135909A1
Автор: NOJIRI Yamato, Takei Mitsuru
Принадлежит: KURARAY NORITAKE DENTAL INC.

The present invention provides a dental cement that exhibits excellent adhesiveness to dentin and has high mechanical strength. The present invention relates to a multi-part dental cement containing: an asymmetric acrylamide-methacrylic acid ester compound (a); an acid group-containing (meth)acrylic polymerizable monomer (b); a hydrophobic crosslinkable polymerizable monomer (c); a chemical polymerization initiator (d); and a filler (e). The asymmetric acrylamide-methacrylic acid ester compound (a) is represented by the following general formula (1): 2. The multi-part dental cement according to claim 1 , wherein X is an optionally substituted claim 1 , linear or branched Cto Caliphatic group.3. The multi-part dental cement according to claim 1 , wherein a content of the asymmetric acrylamide-methacrylic acid ester compound (a) is 2 to 50 parts by weight claim 1 , a content of the acid group-containing (meth)acrylic polymerizable monomer (b) is 1 to 50 parts by weight claim 1 , and a content of the hydrophobic crosslinkable polymerizable monomer (c) is 30 to 95 parts by weight in 100 parts by weight of the total polymerizable monomers.4. The multi-part dental cement according to claim 1 , further comprising a hydrophilic monofunctional polymerizable monomer (f).7. The multi-part dental cement according to claim 4 , wherein a content of the hydrophilic monofunctional polymerizable monomer (f) is 1 to 30 parts by weight in 100 parts by weight of the total polymerizable monomers. The present invention relates to a multi-part dental cement used, for example, for luting dental prostheses such as crowns, inlays, and bridges to tooth structures during dental treatment.For restorative treatment of tooth structures (enamel, dentin, and cementum) damaged, for example, by dental caries, dental cements are used as materials for luting dental prostheses such as crowns, inlays, and bridges to broken or chipped tooth crowns. A dental cement is usually composed of a polymerizable ...

Подробнее
Номер записи: 80
18-05-2017 дата публикации

METHODS FOR VAS-OCCLUSIVE CONTRACEPTION AND REVERSAL THEREOF

Номер: US20170136143A1
Автор: Eisenfrats Kevin Simon, Herr John C., Klibanov Alexander L.
Принадлежит:

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention. 1. A method of occluding a body lumen comprising:imaging an animal or human body lumen;administering a substance into the body lumen; andpolymerizing the substance or forming a mass from the substance in the body lumen.2. The method of claim 1 , wherein the imaging step is performed prior to claim 1 , during claim 1 , and/or after the administering or polymerizing or forming a mass steps.3. The method of claim 1 , wherein as a result of the polymerizing or forming a mass step an occlusion is formed in situ in the body lumen.4. The method of claim 3 , wherein the occlusion is echogenic.5. The method of claim 4 , wherein microbubbles are present in the substance and the microbubbles have an average size in the range from about 1 to about 1 claim 4 ,000 μm in diameter.6. The method of claim 3 , wherein the occlusion comprises a plurality of pores having an average pore size in the range of about 0.1 nm to about 3 μm.7. The method of claim 3 , wherein the occlusion comprises a plurality of pores sized to restrict passage of sperm cells but permit passage of fluids through the pores.8. The method of claim 1 , wherein the substance is a composition having a viscosity in the range of about 1 to 7 Pa*s.9. The method of claim 5 , wherein the microbubbles have a shell comprising a polymer claim 5 , a lipid claim 5 , a protein claim 5 , a surfactant claim 5 , a monosaccharide claim 5 , a polysaccharide claim 5 , or glass.10. The method of claim 1 ...

Подробнее
Номер записи: 81
08-09-2022 дата публикации

Liquid Embolic Compositions

Номер: US20220280163A1
Автор: MORITA Hideo, Tieu Tai D.
Принадлежит: AccuMedical Beijing Ltd.

The present specification discloses improved liquid embolic compositions, methods of making such liquid embolic compositions, and methods and uses for such liquid embolic compositions. 1. A liquid embolic composition comprising:from about 1% to about 20% of a miscible polymer;from about 5% to about 35% of a radiopaque contrast agent;from about 5% to about 93% of a biocompatible solvent; andfrom about 1% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent;wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.2. The liquid embolic composition of claim 1 , wherein the composition comprises:from about 3% to about 10% of a miscible polymer;from about 20% to about 35% of a radiopaque contrast agent;from about 15% to about 57% of a biocompatible solvent; andfrom about 20% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent;wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.3. The liquid embolic composition of claim 1 , wherein the miscible polymer is an ethylene vinyl alcohol copolymer.4. The liquid embolic composition of claim 1 , wherein the contrast agent is at least one of tantalum claim 1 , tantalum oxide claim 1 , barium sulfate claim 1 , gold claim 1 , platinum claim 1 , tungsten claim 1 , palladium claim 1 , and an iodinated contrast agent.5. The liquid embolic composition of claim 1 , wherein the biocompatible solvent is dimethyl sulfoxide or a dimethyl sulfoxide homologue.6. The liquid embolic composition of claim 1 , wherein the mixing agent has a density that is relatively greater than a density of the biocompatible solvent.7. The liquid embolic composition of claim 6 , wherein the mixing agent is at least one of polypropylene plastic claim 6 , polyethylene (“PE”) claim 6 , polyethylene terephthalate (“PET”) claim 6 , polytetrafluoroethylene (“PTFE”) claim 6 ...

Подробнее
Номер записи: 82
26-05-2016 дата публикации

FILMS AND METHODS OF MANUFACTURE

Номер: US20160144067A1
Автор: Armbruster David, Chomyn Jeffrey, DWYER (Deceased) James, Kerr Sean H.
Принадлежит:

Embodiments of the present disclosure are directed to perforated polymer films and methods of making the same. In some embodiments, the films are for use with implantable medical devices. In one embodiment there is a flexible body including a polymer film having a first surface and an opposing second surface, the film having a plurality of apertures extending from the first surface to the second surface and a plurality of raised lips protruding from the first surface such that each of the plurality of apertures is surrounded by a one of the plurality of raised lips. In one embodiment, the film comprises a single layer, and in another embodiment, the film can comprise a plurality of layers. In certain embodiments, the film can comprise an adhesive layer. In another embodiment, one or more of the layers may be a drug containing layer and/or a rate controlling layer for drug release. 1. A flexible body comprising:a film having a first surface and an opposing second surface, the film having a plurality of apertures extending from the first surface to the second surface and a plurality of raised lips protruding from the first surface such that each of the plurality of apertures is surrounded by a one of the plurality of raised lips;wherein the film comprises a plurality of layers,wherein at least one of the plurality of layers includes a drug containing layer containing a drug, and,wherein at least one of the plurality of layers includes an adhesive layer.2. The flexible body of claim 1 , wherein the adhesive layer defines one of the first surface and the second surface.3. The flexible body of claim 1 , wherein at least one of the plurality of layers includes a rate controlling layer configured to control a rate release of the drug.4. The flexible body of claim 1 , wherein the film comprises a biodegradable polymer.5. The flexible body of claim 4 , wherein the drug is at least partially insoluble in the polymer.6. The flexible body of claim 1 , wherein the film further ...

Подробнее
Номер записи: 83
24-05-2018 дата публикации

INTRA-ABDOMINAL PRESSURE TO PROMOTE HEMOSTASIS AND SURVIVAL

Номер: US20180140740A1
Автор: Helmick Marc, Marini John, RAGO Adam, Sharma Upma, Zugates Gregory T.
Принадлежит:

Systems, methods and kits for treating hemorrhages within cavities are provided. The methods utilize the application of a rapid spike of pressure to the closed cavity, followed by a steady state pressure or pressures. 1. A method of treating a hemorrhage within a cavity , comprising the steps of: applying a pressure to an interior boundary of the cavity , wherein the pressure is applied by applying a material to the interior boundary , and wherein the pressure is characterized by a transient peak value and at least one steady state value.2. The method of claim 1 , wherein the transient peak value less than about 84 mmHg.3. The method of claim 1 , wherein the transient peak value is at least about 51 mmHg.4. The method of claim 1 , wherein the transient peak value is at least about 20 mmHg5. The method of claim 1 , wherein the steady state value is at least about 28 mmHg.6. The method of claim 1 , wherein the steady state value is at least about 14 mmHg.7. The method of claim 1 , wherein the transient peak value occurs within the first three minutes and is followed by the steady state value.8. The method of claim 7 , wherein the steady state value is at least 30% of the transient peak value.9. The method of claim 7 , wherein the steady state value is at least 50% of the transient peak value.10. The method of claim 7 , wherein the steady state value is at least 90% of the transient peak value.1112-. (canceled)13. The method of claim 1 , wherein the cavity is an abdominal cavity claim 1 , a junctional hemorrhage claim 1 , a cavity associated with a pelvic hemorrhage claim 1 , or a pseudocavity.14. A kit for treating hemorrhage in a cavity of a patient claim 1 , the kit comprising: a material configured to apply a pressure to an interior boundary of a body cavity; and instructions instructing a user to perform the method of .15. The kit of claim 14 , wherein the pressure is characterized by a transient peak value followed by a steady state value.16. The kit of claim 15 ...

Подробнее
Номер записи: 84
04-06-2015 дата публикации

FUNCTIONALIZED SURGICAL ADHESIVES

Номер: US20150151019A1
Автор: Ladet Sébastien
Принадлежит:

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition. 145-. (canceled)46. A bioadherent composition which comprises:a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a first ligand capable of binding a first receptor on biological tissue; anda second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a second ligand capable of binding a second receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.47. The bioadherent composition according to wherein the members of the specific binding pair bind to one another via a Huisgen cycloaddition reaction claim 46 , a Diels-Alder reaction and a thiol-ene reaction.48. The bioadherent composition according to wherein the members of the specific binding pair are alkynes and azides.49. The bioadherent composition according to wherein the reactive member is an alkyne and the complementary reactive member is an azide.50. The bioadherent composition according to wherein the reactive members ...

Подробнее
Номер записи: 85
04-06-2015 дата публикации

FORMED SHEET PRODUCT AND HEMOSTATIC MATERIAL

Номер: US20150151020A1
Автор: Akiyama Yusuke, Fujinaga Kentaro, HIRASHIMA MASAKI, HONDA Susumu, Imamura Takayuki, Kageyama Yukako, Kaneko Hiroaki, Kawamura Ryoichi, OONO Akitoshi, Satake Makoto, YAMAGUCHI Ayuko
Принадлежит:

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material. 1. A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer.2. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of a cellulose derivative claim 1 , a polymer having an N-vinyl cyclic lactam unit claim 1 , polyethylene oxide claim 1 , polyvinyl alcohol claim 1 , hyaluronic acid claim 1 , dextran claim 1 , pullulan claim 1 , starch claim 1 , and a mixture thereof.3. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose claim 1 , sodium carboxymethyl cellulose claim 1 , and a mixture thereof.4. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of polyglycolic acid claim 1 , polylactic acid claim 1 , polycaprolactone ...

Подробнее
Номер записи: 86
25-05-2017 дата публикации

Collagen Sponge Containing a Drug for Promoting Fracture Healing and Method for Preparing the Same

Номер: US20170143869A1
Автор: GUAN Hongxia, Liu Yansong, Xia Zhidao, ZHANG Yingze
Принадлежит:

Provided are a collagen sponge containing a drug for promoting fracture healing and a method for preparing the same, the method comprises the steps of: 1) adding bisphosphonate containing phosphonate radical in an equivalent dosage of 70 to 140 mg and/or strontium salt in a dosage of 100 to 800 mg into 1 kg of the enzymolysis solution of collagen; 2) adding a crosslinking agent into the solution, the crosslinking agent being added in a proportion where 40 to 60 U of crosslinking agent is added per gram of enzymolysis solution; 3) stirring the mixed solution in step 2) uniformly, then putting it into a stainless steel tray, and placing the tray in a vacuum lyophilizer for lyophilizing for 10 to 16 hours so that it is lyophilized into a sponge-like shape; and 4) allowing the collagen sponge in step 3) to be cut, packaged and sealed, and sterilized by irradiation with cobalt 60. 1. A collagen sponge containing a drug for promoting fracture healing , comprising the following components: an enzymolysis solution of collagen , a bisphosphonate and/or a strontium salt , and a crosslinking agent; the collagen sponge is prepared by: adding the bisphosphonate and/or the strontium salt into the enzymolysis solution of collagen in a proportion where , for 1 kg of the enzymolysis solution of collagen , the equivalent dosage of phosphonate radical in the bisphosphonate is 70 to 140 mg/kg , and the dosage of the strontium salt is 100 to 800 mg/kg , and adding 40 to 60 U of transglutaminase as the crosslinking agent per gram of the enzymolysis solution of collagen; wherein the ratio of an enzymatic hydrolysate of collagen to water is 1:9 to 1:8; the bisphosphonate includes sodium etidronate , sodium clodronate , sodium pamidronate , sodium tiludronate , alendronate sodium , neridronate sodium , olpadronate sodium , risedronate sodium and ibandronate sodium; and the strontium salt includes strontium chloride and strontium ranelate.2. The collagen sponge containing a drug for ...

Подробнее
Номер записи: 87
16-05-2019 дата публикации

MEDICAL HYDROGEL COMPOSITION, AND MEDICAL HYDROGEL, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Номер: US20190142994A1
Автор: Deng Kunxue, LIN Limin, Ma Cheng, Yang Yaya, Yuan Yuyu
Принадлежит: Medprin Regenerative Medical Technologies Co., Ltd.

A medical hydrogel composition, a medical hydrogel, a preparation method therefore and an application thereof, and a medical hydrogel kit. The medical hydrogel composition comprises a first component and a second component; the first component comprises polylysine and polyethylene imine; the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, and 4-arm-polyethylene glycol-succinimidyl carbonate; the degree of polymerization of the polylysine is 20 or more. The medical hydrogel is formed by reacting the first component with the second component of the medical hydrogel composition. The medical hydrogel kit comprises the medical hydrogel composition and a buffer solution used for dissolving the components of the medical hydrogel composition. The medical hydrogel has a degree of swelling of −10%-50%, and can be applied in narrow parts where cranial, spinal, and peripheral nerves are densely distributed. 1. A medical hydrogel composition , wherein the medical hydrogel composition comprises a first component and a second component , the first component comprises polylysine and polyethylene imine , the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate , 4-arm-polyethylene glycol-succinimidyl succinate , and 4-arm-polyethylene glycol-succinimidyl carbonate , and wherein the polylysine has a degree of polymerization of 20 or more , preferably 25 to 35.2. The medical hydrogel composition according to claim 1 , wherein in the first component claim 1 , a mass ratio of the polylysine to the polyethylene imine is 0.1 to 10.3. The medical hydrogel composition according to claim 1 , wherein the polylysine is ε-polylysine and/or poly-L-lysine.4. The medical hydrogel composition according to claim 3 , wherein the weight average molecular weight of the ε-polylysine is 3000 to 5000 Da.5. The medical hydrogel composition according to claim 3 , wherein the ...

Подробнее
Номер записи: 88
31-05-2018 дата публикации

PARTICLES

Номер: US20180147317A1
Автор: Cruise Gregory M., Plotkin Steve, Wu Xinping
Принадлежит:

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer. 1. An embolic system including:a catheter; and a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and', 'at least one monomer,, 'spherical embolic particles including a reaction product of a prepolymer solution includingwherein the spherical embolic particles have a diameter between about 50 μm and about 1,500 μm.2. The embolic system of claim 1 , wherein the diameter is between about 400 μm and about 1 claim 1 ,500 μm.3. The embolic system of claim 1 , wherein the catheter is a microcatheter.4. The embolic system of claim 1 , wherein the at least one monomer includes ionic groups.5. The embolic system of claim 4 , wherein the monomer containing ionic groups is sodium acrylate.6. The embolic system of claim 1 , wherein the prepolymer solution further includes a crosslinker7. The embolic system of claim 6 , wherein the crosslinker is biodegradable.10. A method of treatment claim 6 , the method comprising:delivering spherical embolic particles through a catheter to a treatment site, a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and', 'at least one monomer,, 'wherein the spherical embolic particles are formed from a reaction product of a prepolymer solution includingwherein the spherical embolic particles have a diameter between about 50 μm and about 1,500 μm.11. The method of claim 10 , wherein the delivering includes flushing the catheter with a non-solvent.12. The method of claim 11 , wherein the non-solvent is a mineral oil claim 11 , hexane claim 11 , or water.13. The ...

Подробнее
Номер записи: 89
11-06-2015 дата публикации

Curing Accelerator and Method of Making

Номер: US20150157760A1
Автор: Azevedo Max, Ruiz, SR. Rafael, Zhang Sheng
Принадлежит:

The invention concerns sterilized cyanoacrylate adhesive compositions comprising 99% or more by weight, based on the weight of the adhesive composition, of 2-octyl cyanoacrylate, mixed together with butylated hydroxyl anisole, sulfur dioxide, and 100 to 1000 parts per million, based on the weight of the adhesive composition, of a 18-crown-6 crown ether, wherein the composition is sterilized by irradiation as well as methods of making and using such compositions. 1. (canceled)2. A sterilized cyanoacrylate adhesive composition , comprising99% or more by weight, based on the weight of the adhesive composition, of 2-octyl cyanoacrylate, mixed together withfree radical stabilizer,anionic vapor phase stabilizer, and100 to 1000 parts per million, based on the weight of the adhesive composition, of a 18-crown-6 crown ether, 'wherein the sterilized cyanoacrylate adhesive composition does not cure upon sterilization.', 'wherein the composition is sterilized by irradiation, and'}3. The sterilized cyanoacrylate adhesive composition of claim 2 , wherein the adhesive remains fluid following storage for twelve days at 80° C.4. The sterilized cyanoacrylate adhesive composition of claim 2 , wherein the anionic vapor phase stabilizer is present in the composition at a concentration of less than 20 parts per million.5. The sterilized cyanoacrylate adhesive composition of claim 2 , wherein the free radical stabilizer is butylated hydroxyl anisole.6. The sterilized cyanoacrylate adhesive composition of claim 2 , wherein the anionic vapor phase stabilizer is sulfur dioxide.7. The sterilized cyanoacrylate adhesive composition of claim 2 , further comprising therapeutic-loaded nanoparticles.8. The sterilized cyanoacrylate adhesive composition of claim 2 , wherein the composition has been treated with a particulate agent selected from the group consisting of vinyl pyrrolidone polymers and co-polymers.9. The sterilized cyanoacrylate adhesive composition of claim 2 , wherein the irradiation ...

Подробнее
Номер записи: 90
21-08-2014 дата публикации

Composite Collagen Sponge and Preparation Method Thereof

Номер: US20140235539A1
Автор: WANG Shanshan
Принадлежит:

The present invention discloses a composite collagen sponge and the preparation method thereof. The composite collagen sponge comprises collagen, cell growth factors, and a protecting agent, and has a water absorption capacity of more than 52 times. The preparation method includes a cation chromatographic purification step and a two-stage inactivation step consisting of organic solvent/detergent virus inactivation and dry heat virus inactivation. The composite collagen sponge obtained by the method of the present invention not only improves the safety and performance of the product in clinical applications, but also ensures the stability and the bioactivity throughout the effective life of the product. 1. A composite collagen sponge comprising collagen and at least one cell growth factor , the composite collagen sponge having a water absorption capacity of more than 52 times the weight of the composite collagen sponge absorbing water.2. The composite collagen sponge according to claim 1 , having an elastic modulus of more than 70.0 N/cm.3. The composite collagen sponge according to claim 2 , further comprising a protecting agent comprising at least one amino acid claim 2 , at least one saccharide claim 2 , and an albumin in a weight ratio of (1 to 11):(1.25 to 17.5):(1 to 7.5).4. (canceled)5. The composite collagen sponge according to claim 3 , wherein the protecting agent further comprises glycerol.6. (canceled)7. A method for preparing the composite collagen sponge according to claim 1 , the method comprises:forming a collagen solution,purifying the collagen solution using ion exchange chromatograph with an eluent comprising, sodium chloride at a concentration of from 0.2 mol/L to 0.8 mol/L and sodium acetate at a concentration of 0.1 mol/L, wherein the ion exchange chromatogrpahy is a preparative chromatography with CM52 cation exchange resins, and wherein the eluent has a pH of 4.5.8. The method for preparing the composite collagen sponge according to claim 7 , ...

Подробнее
Номер записи: 91
09-06-2016 дата публикации

SELF-ASSEMBLING BIOMIMETIC HYDROGELS HAVING BIOADHESIVE PROPERTIES

Номер: US20160158406A1
Автор: IFTODE Cristina, JOHNSON Bryan, KADLOWEC Jennifer, KUBINSKI Pamela, TULENKO Thomas N., VERNENGO Andrea Jennifer, WILTSEY Craig
Принадлежит: ROWAN UNIVERSITY

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection of a liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101.-. (canceled)103. The method of claim 102 , wherein said delivering is to a human disc in vivo.104. The method of claim 102 , wherein the TD polymer is selected from the group consisting of poly(ethylene oxides) (PEOs) claim 102 , poly(propylene oxides) (PPOs) claim 102 , copolymers of PEO and poly(lactic acid) (PLA) claim 102 , poly(n-isopropyl acrylamides) (PNIPAAms) claim 102 , mixtures of the foregoing claim 102 , and copolymers of the foregoing.105. The method of claim 102 , wherein the TD polymer is covalently linked with an ECM polymer.106. The method of claim 105 , wherein the ECM polymer is the same polymer as the polymeric component.108. The method of claim 107 , wherein said composition further comprises: ...

Подробнее
Номер записи: 92
22-09-2022 дата публикации

ELECTROACTIVE BIOADHESIVE COMPOSITIONS

Номер: US20220296771A1
Автор: MANDLER Daniel, STEELE Terry W.J.
Принадлежит:

Electrochemically initiated bioadhesive compositions comprising biocompatible polymers containing derivatives of diazonium, arylsulfonium, or diaryliodonium in general, and to their use in tissue fixation, in particular. 1. An electroactive bioadhesive composition comprising an electroactive biocompatible polymer comprising a biocompatible polymer and suitable solvents , surfactants , stabilizers , fillers and/or other additives;wherein the biocompatible polymer comprises a single strand of repeating units and up to 5,000 electroactive groups covalently attached to said strand, wherein precursors of said electroactive groups are selected from the group consisting of a diazonium derivative, an arylsulfonium derivative, a diaryliodonium derivative, and combinations thereof;wherein the biocompatible polymer is selected from the group consisting of poly-L-lactic acid (PLLA), poly(lactide-co-glycolide) (PLGA), poly caprolactone (PCL), polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), collagen, hydroxy propyl cellulose, polyglycerol esters of fatty acids, polysaccharides, and combinations thereof.2. The electroactive bioadhesive composition according to claim 1 , wherein said additives are anti-inflammatory drugs claim 1 , anti-proteases claim 1 , antibiotics claim 1 , or anti-restenosis compounds.3. The electroactive bioadhesive composition according to claim 1 , wherein said composition is in a form of hydrogel.4. The electroactive bioadhesive composition according to claim 1 , wherein said composition is in a form of biocompatible film claim 1 , patch or bondage.5. The electroactive bioadhesive composition according to claim 1 , further comprising conductive particles or polymers of less than 50 micron comprised of gold claim 1 , iron claim 1 , iron oxides claim 1 , platinum claim 1 , magnesium claim 1 , graphene claim 1 , carbon black claim 1 , carbon nanotubes claim 1 , polyacetylene claim 1 , poly(3-alkyl-thiophene) claim 1 , polyaniline claim 1 , ...

Подробнее
Номер записи: 93
08-06-2017 дата публикации

MIXING DEVICE WITH OPERATING ELEMENT AND PRESSURE PUMP FOR MIXING POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20170156778A1
Автор: Kluge Thomas, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

The invention relates to a mixing device for mixing PMMA bone cement from a monomer liquid and a cement powder, the mixing device comprising at least one cartridge having an evacuable interior for mixing of the bone cement, a mixing device for mixing the content in the interior of the at least one cartridge, which is arranged movably in the interior, a receptacle for receiving a separate container containing the monomer liquid or comprising an integrated container containing the monomer liquid, an opening device, which is arranged in the region of the receptacle in a manner movable relative to the receptacle so that, by moving the opening device, a separate container arranged in the receptacle is openable by means of the opening device, or the opening device is arranged in the region of the integrated container in a manner movable relative to the integrated container so that, by moving the opening device, the integrated container is openable by means of the opening device, a pressure pump, in which a movable plunger for conveying a liquid is arranged and delimits a pump chamber of the pressure pump and a connection line, which connects the interior of the at least one cartridge to the pump chamber of the pressure pump, wherein the mixing device comprises an operating element that is operatable from outside, wherein the plunger in the pressure pump is movable manually by means of the operating element, and wherein the opening device is to be moved relative to the receptacle or relative to the integrated container by means of the same operating element, and the mixing device in the interior of the cartridge is movable by means of the same operating element in order to mix the content in the interior of the cartridge.

Подробнее
Номер записи: 94
08-06-2017 дата публикации

VACUUM MIXING DEVICE WITH OPERATING ELEMENT AND PUMP FOR MIXING POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20170157578A1
Автор: Kluge Thomas, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

A vacuum mixing device for mixing PMMA bone cement from a monomer liquid and a cement powder, the vacuum mixing device comprising at least one cartridge comprising an evacuable interior for mixing of the bone cement, a mixing device for mixing the content in the interior of the at least one cartridge, which is arranged movably in the interior, a receptacle for receiving a separate container containing the monomer liquid or comprising an integrated container containing the monomer liquid, an opening device, which is arranged in the region of the receptacle in a manner movable relative to the receptacle so that, by moving the opening device, a separate container arranged in the receptacle is openable by means of the opening device, or the opening device is arranged in the region of the integrated container in a manner movable relative to the integrated container so that, by moving the opening device, the integrated container is openable by means of the opening device, a pump, in which a movable plunger for generating a negative pressure is arranged and delimits a pump chamber of the pump, and a connection line, which connects the interior of the at least one cartridge to the pump chamber of the pump, wherein the vacuum mixing system comprises an operating element that is operatable from outside, wherein the plunger in the pump is movable manually by means of the operating element, and wherein the opening device is movable relative to the receptacle or relative to the integrated container by means of the same operating element, and the mixing device in the interior of the cartridge is movable by means of the same operating element in order to mix the content in the interior of the cartridge. 1. A vacuum mixing device for mixing polymethylmethacrylate bone cement from a monomer liquid and a cement powder , the vacuum mixing device comprisingat least one cartridge comprising an evacuable interior for mixing of the bone cement,a mixing device for mixing the content in the ...

Подробнее
Номер записи: 95
08-06-2017 дата публикации

VACUUM MIXING DEVICE WITH OPERATING ELEMENT, PRESSURE PUMP, AND VACUUM PUMP FOR MIXING POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20170157579A1
Автор: Kluge Thomas, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

A vacuum mixing device or system mixes polymethylmethacrylate bone cement from a monomer liquid and a cement powder. The device or system comprising at least one cartridge comprising an evacuable interior for mixing of the bone cement, a mixing device for mixing the content in the interior of the at least one cartridge, a receptacle for receiving a separate container containing the monomer liquid or comprising an integrated container containing the monomer liquid, an opening device, which is arranged in the region of the receptacle in a manner movable relative to the receptacle so that, by moving the opening device, a separate container arranged in the receptacle is openable by means of the opening device, or the opening device is arranged in the region of the integrated container in a manner movable relative to the integrated container so that, by moving the opening device, the integrated container is openable by means of the opening device, a vacuum pump, in which a movable vacuum plunger for generating a negative pressure is arranged and delimits a vacuum pump chamber of the vacuum pump, a pressure pump, in which a movable pump plunger for conveying a liquid is arranged and delimits a pressure pump chamber of the pressure pump, a connection line, and a fluid connection. The device or system further comprises an operating element that is operatable from outside, wherein, by means of the operating element, the vacuum plunger in the vacuum pump is movable manually, the pump plunger in the pressure pump is movable manually, the opening device is movable manually relative to the receptacle or relative to the integrated container, and the mixing device is movable manually in the interior of the cartridge. 1. A vacuum mixing device for mixing polymethylmethacrylate bone cement from a monomer liquid and a cement powder , the vacuum mixing device comprising:at least one cartridge having an evacuable interior for mixing of the bone cement,a mixing device for mixing the ...

Подробнее
Номер записи: 96
25-06-2015 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20150174289A1
Автор: DeAnglis Ashley, Doron Sivan, Nur Israel, Pilpel Yair, Zherdev Yuri
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 1. A liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide or other reversible fibrin polymerization blocking agent; wherein the blocking agent or GPRP is present in the formulation in an amount which is greater than 100 fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.2. The formulation of claim 1 , wherein the GPRP peptide is present in an amount greater than about 340 fold molar excess relative to the fibrin monomers.3. The formulation of claim 1 , wherein the GPRP peptide is present in an amount of about 340 to 460 fold molar excess relative to the fibrin monomers.4. The formulation of claim 1 , wherein the formulation is substantially free of added thrombin.5. The formulation of claim 1 , further comprising thrombin-activated Factor XIII.6. The formulation of claim 1 , further comprising a calcium chelator.7. The formulation of claim 6 , wherein the calcium chelator is a citrate ion.8. The formulation of claim 7 , wherein the citrate ion is provided by sodium citrate.9. The formulation of claim 8 , comprising from about 1 mM to about 50 mM sodium citrate.10. The formulation of claim 1 , wherein the formulation has a neutral pH.11. The formulation of claim 1 , for use in hemostasis claim 1 , sealing claim 1 , healing and/or in surgery.12. A container comprising the formulation of .13. A kit comprising the container of claim 12 , and optionally instructions for use.14. A method for preparing a sealant at a surface comprising providing the formulation of ; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at ...

Подробнее
Номер записи: 97
22-06-2017 дата публикации

ANTIBIOTIC POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20170173210A1
Автор: KLIMAS SUSANN, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

The invention proposes an antibiotic polymethylmethacrylate bone cement that is composed of methylmethacrylate, at least one polymethylmethacrylate or a polymethylmethacrylate-copolymer, at least one polymerisation initiator, such as in radical initiator, at least one polymerisation accelerator, and at least one radiopaquer, whereby the components are present in a powdered component and a liquid monomer component or in two components that are pasty at room temperature. The polymethylmethacrylate bone cement according to the invention comprises the cyclical lipopeptide, daptomycin, a pharmacologically tolerable salt of daptomycin, a solvate and/or a hydrate containing daptomycin and at least one calcium salt, which preferably comprises at least two different release profiles. 1. Antibiotic polymerisable bone cement , comprising:(i) at least one monomer for radical polymerisation;(a2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and(iii) at least one polymerisation initiator;(iv) at least one radiopaquer;wherein '(v) as component 1, daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin; and', 'the bone cement comprises,'}(vi) at least one calcium salt.2. Bone cement according to claim 1 , wherein the bone cement comprises claim 1 , as (vi) a combination comprising:a) as component 2, a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, andb) as component 3, a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, and, optionally,c) at least one of components 1, 2 and/or 3 has a mean particle size of 1 to 250 μm.3. Bone cement according to claim 1 , which comprises two components A and B claim 1 , whereby (a1) at least one monomer for radical polymerisation;', '(a2) at least one organic polymer ...

Подробнее
Номер записи: 98
02-07-2015 дата публикации

EMBOLIZATION

Номер: US20150182658A1
Автор: Casey, II Thomas V., Lanphere Janel, Rioux Robert F.
Принадлежит:

A particle includes a ferromagnetic material, a radiopaque material, and/or an MRI-visible material. 1. A particle , comprising:a ferromagnetic material in the form of a liquid, a fiber or a flake,wherein (a) the particle has a center region, a surface region and a diameter of at most about 3,000 microns, (b) the particle includes between about one percent by weight and about 25 percent by weight of the ferromagnetic material, and (c) the concentration of the ferromagnetic material varies from the center region of the particle to the surface region of the particle.2. The particle of claim 1 , wherein the particle further comprises a gel.3. The particle of claim 1 , wherein the particle further comprises a therapeutic agent.4. The particle of claim 1 , wherein the particle is substantially spherical.5. The particle of claim 1 , wherein the particle further comprises a coating comprising the ferromagnetic material.6. The particle of claim 1 , wherein the concentration of the ferromagnetic material is higher in the center region of the particle than the surface region of the particle.7. The particle of claim 1 , wherein the ferromagnetic material is selected from the group consisting of transition metals claim 1 , metal alloys and metal oxides.8. The particle of claim 1 , wherein the ferromagnetic material is selected from the group consisting of magnetite claim 1 , nickel claim 1 , cobalt claim 1 , iron and Mu-metal.9. The particle of claim 1 , wherein the ferromagnetic material is selected from the group consisting of soft ferrites claim 1 , rare-earth magnet alloys and amorphous and non-earth alloys.10. The particle of claim 1 , wherein the ferromagnetic material is distributed within a polymeric matrix.11. The particle of claim 10 , wherein the ferromagnetic material is substantially homogeneously distributed throughout the polymeric matrix.12. The particle of wherein the polymeric matrix comprises a polysaccharide.13. The particle of claim 10 , wherein the ...

Подробнее
Номер записи: 99
28-06-2018 дата публикации

ADHESIVE COMPOSITION

Номер: US20180177913A1
Автор: ADJILI Salim, PEREIRA Maria
Принадлежит:

A composition with improved adhesive and sealant properties comprising a) a pre-polymer comprising a polymeric unit of the general formula (-A-B—), wherein A represents a substituted or un-substituted ester, B represents a substituted or un-substituted acid ester comprising at least two acid ester functionalities, and n represents an integer greater than 1, and b) an anhydride compound. 127-. (canceled)28. A composition comprising:{'sub': 'n', 'a) a pre-polymer comprising a polymeric unit of the general formula (-A-B—), wherein A represents a substituted or un-substituted ester, B represents a substituted or un-substituted acid ester comprising at least two acid ester functionalities, and n represents an integer greater than 1, and'}b) an anhydride compound.30. The composition according to claim 29 , wherein p is an integer from 4-10.31. The composition according to claim 30 , wherein p=8.35. The composition according to claim 28 , wherein the anhydride compound comprises a grafted anhydride compound.36. The composition according to claim 35 , wherein the molar ratio of grafted anhydride compound is greater than about 0.02 mol/mol of polyacid.37. The composition according to claim 36 , wherein the molar ratio of grafted anhydride compound is greater than about 0.1 mol/mol of polyacid.38. The composition according to claim 28 , wherein the anhydride compound comprises an asymmetric anhydride claim 28 , wherein the molar content of the asymmetric anhydride is greater than about 30% of the total content of dried anhydrides.39. The composition according to claim 28 , wherein the anhydride compound comprises a non-grafted anhydride compound.40. The composition according to claim 39 , wherein the non-grafted anhydride compound is selected from acrylic anhydride claim 39 , methacrylic anhydride claim 39 , 4-methacryloyloxyethyl trimellitate anhydride claim 39 , succinic anhydride claim 39 , maleic anhydride or any combination thereof.41. The composition according to claim ...

Подробнее
Номер записи: 100